Introduction {#s1}
============

The bacterial pathogen *Mycobacterium tuberculosis* (*Mtb*) is the causative agent of tuberculosis, an ongoing world health problem. RNA polymerase (RNAP), responsible for all transcription in bacteria, is the target of the rifamycin class of antibiotics, a first-line therapeutic treatment for tuberculosis ([@bib10]). Thus, RNAP is a proven drug target, highlighting the importance of gaining a structural and functional understanding of mycobacterial transcription - an understanding made difficult by the lack of a mycobacterial RNAP structure.

Bacterial transcription initiation is controlled by promoter-specificity σ-factors, which associate with the core RNAP (α~2~ββ'ω subunits), generating the holoenzyme (holo; [@bib26]; [@bib48]). Promoter DNA sequences are recognized by holo ([@bib49]), triggering a series of conformational changes as the enzyme unwinds 12 to 14 base pairs of DNA to generate the transcription bubble and loads the template-strand (t-strand) DNA into the RNAP active site, resulting in the transcriptionally-competent open promoter complex (RPo; [@bib60]).

The vast majority of mechanistic studies on bacterial transcription initiation have used *Escherichia coli* (*Eco)* RNAP as a model. However, the properties of *Eco* RNAP are not necessarily representative of RNAPs from other bacterial species ([@bib16]; [@bib64]; [@bib78]). In contrast to *Eco* holo, which forms an essentially irreversible RPo on many promoters, the mycobacterial holo forms an unstable RPo with a half-life of a few minutes or less when compared with *Eco* holo on the same promoters ([@bib16]). Two transcription factors, CarD and RbpA, both essential in mycobacteria but absent in *Eco*, potentiate the activity of the mycobacterial RNAP ([@bib22]; [@bib71]; [@bib73]).

CarD associates with RNAP through its interaction with β-lobe 1 (also known as the protrusion; [@bib4]; [@bib72]) and stabilizes RPo by wedging a conserved Trp residue into the widened minor groove at the upstream edge of the transcription bubble ([@bib4]). RbpA forms a tight interaction with the σ~2~ domain (−10 element recognition domain) of Group 1 and Group 2 σ factors through its C-terminal σ-interacting domain (SID; [@bib7]; [@bib29]; [@bib73]), but how other RbpA structural elements interact with the transcription initiation complex (TIC) and activate transcription is unknown.

ChIP-Seq studies indicate CarD is present at most, if not all, σ^A^ promoters in mycobacteria ([@bib70]). Comprehensive genomic data for RbpA occupancy in vivo is not available, but RbpA forms a very tight complex with σ^A^ and σ^A^-holo ([@bib29]) and is likely present at most σ^A^ promoters as well. Thus, the structural mechanism for CarD and RbpA function must be compatible with the two transcription activators acting simultaneously on the mycobacterial TIC.

Here, we determined a 2.76 Å-resolution crystal structure of a mycobacterial TIC with RbpA. Structural analysis along with a combination of in vitro and in vivo functional approaches was used to extend our understanding of the roles of RbpA and CarD in regulating mycobacterial transcription. We show that RbpA and CarD cooperatively stimulate formation of an intermediate leading to RPo, a step defective in promoters lacking a −35 element, which represents the majority of mycobacterial promoters ([@bib12]). This work provides an unprecedented structural framework to understand mycobacterial transcription and insight into why RbpA is essential.

Results {#s2}
=======

Crystal structure of the *M. smegmatis* RbpA/TIC {#s2-1}
------------------------------------------------

Avirulent *M. smegmatis* (*Msm*) is not a viable model organism for *Mtb* pathogenesis but the *Msm* RNAP and associated transcription system is an excellent model for *Mtb* transcription ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). To provide a structural basis for understanding mycobacterial transcription initiation, we crystallized and determined the 2.76 Å-resolution structure of a 446 kDa *Msm* TIC containing RbpA, σ^A^-holo, and an upstream fork junction promoter fragment ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A--C](#fig1s1){ref-type="fig"}, [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). Analysis of the structure provides several highlights that will be described elsewhere. Here we focus on the role of RbpA in the context of the TIC ([Figure 1](#fig1){ref-type="fig"}).10.7554/eLife.22520.002Figure 1.Structure of the *Msm* RbpA/TIC.(**A**) (top) The RbpA structural architecture is represented schematically. The CD is shown as a thick region, with β-strands represented as arrows. The α-helices of the SID are shown as rectangles. Linker regions lacking secondary structure, the NTT and BL, are represented by a thin line. The NTT is disordered in the crystal structure and is shown as a dashed line. Conserved basic residues in the BL (K74, K76, R79) that interact with the DNA phosphate backbone are denoted. (bottom) Overall structure of the *Msm* RbpA/TIC. The color-coding of most of the structural features is denoted in the legend. Protein components (core RNAP, σ^A^, RbpA) are shown as molecular surfaces. The surfaces of RbpA and the lineage-specific insert β'i1 are transparent, revealing the α-carbon backbone ribbon underneath. RbpA side chains K74, K76, and R79 are shown in stick format. The DNA is shown as CPK atoms, with the −35 and −10 elements colored yellow. (**B**) Magnified view of the region including RbpA and the promoter DNA near the −10 element. The DNA is shown in stick format. The β'ZBD surface is transparent with the Zn^2+^-ion shown as a sphere.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.002](10.7554/eLife.22520.002)10.7554/eLife.22520.003Figure 1---figure supplement 1.Crystallization oligonucleotides, electron density maps, and RbpA sequence conservation.(**A**) Synthetic oligonucleotides used for the *Msm* RbpA/TIC crystallization. The DNA sequence is derived from the full con promoter ([@bib23]). The nt-strand DNA (top strand) is colored dark gray; the t-strand DNA (bottom strand), light grey. The −35 and −10 elements are shaded yellow. The extended −10 ([@bib35]) is colored green. (**B**) Stereo view of the refined 2*F*~o~ -- *F*~c~ map (light blue mesh, contoured at 1σ), with superimposed structure showing the RbpA^BL^ residues K74, K76, and R79 interactions with the DNA phosphate backbone. (**C**) Stereo view of the refined 2*F*~o~ -- *F*~c~ map (light blue mesh, contoured at 1σ), with superimposed structure showing the RbpA^CD^ interface with the β'ZBD and β'zipper region. (**D**) Sequence logo (top) derived from an alignment of 890 RbpA orthologs. Below are shown the *Mtb* and *Msm* RbpA sequences and at the bottom, the RbpA structural elements (NTT, CD, BL, SID). The filled dots above the sequences denote RbpA residues that interact with the β'ZBD/β'zipper region (green dots) or σ^A^ (blue dots).**DOI:** [http://dx.doi.org/10.7554/eLife.22520.003](10.7554/eLife.22520.003)

RbpA comprises four structural elements, the N-terminal tail (NTT), the core domain (CD), the basic linker (BL), and the SID ([Figure 1A](#fig1){ref-type="fig"}). The RbpA^SID^ association with σ^A^~2~ matches closely the previously determined RbpA^SID^/σ^A^~2~ crystal structure (PDB ID 4X8K; [@bib29]), with an rmsd of 0.451 Å over 152 Cα atoms. N-terminal to the RbpA^SID^, we built the RbpA^BL^ and fit the previously determined structure of the *Mtb* RbpA^CD^ (residues 26--69; PDB ID 2M4V; ([@bib7]); rmsd of 0.775 Å over 40 Cα atoms after final refinement; [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) into clear electron density ([Figure 1---figure supplement 1B--C](#fig1s1){ref-type="fig"}), but density was absent for the 25-residue RbpA^NTT^.

The RbpA^CD^ makes extensive contacts with the β' Zinc-binding domain (β'ZBD) as well as with residues flanking the β'zipper ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}), structural elements of the RNAP 'clamp' module ([@bib14]; [@bib24]) near the N-terminus of β' that are conserved among bacterial RNAPs ([@bib39], [@bib40]). The RbpA^CD^/β' interface buries a surface area of 615 Å^2^. Together with the RbpA^SID^/σ^A^~2~ interface (954 Å^2^ buried surface area), RbpA forms a bipartite protein/protein interface with holo that buries a total surface area of 1569 Å^2^. An alignment of RbpA from 890 bacterial genomes indicates that the CD is 55% identical, but residues that contact the ZBD and zipper are 80% identical ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}), indicating that the observed RbpA^CD^/β' interface is a conserved feature of the RbpA/RNAP interaction.

Although the RbpA^CD^/β' interactions may modulate transcription initiation, such a role is not evident solely from examination of the structure. What is evident from the structure is that the RbpA/RNAP interactions position the RbpA^BL^ (residues 70--79) to interact with the DNA phosphate backbone just upstream of the −10 element ([Figure 1B](#fig1){ref-type="fig"}).

RbpA-R79 anchors the DNA upstream of the transcription bubble {#s2-2}
-------------------------------------------------------------

In the *Msm* RbpA/TIC, absolutely conserved RbpA-R79 ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}) makes a close (2.2 Å) polar interaction with the negatively charged phosphate between the −13 and −14 positions of the non-template strand (nt-strand) DNA ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), explaining previous findings that RbpA-R79 was important for the ability of RbpA to increase the overall affinity of mycobacterial holo to promoter DNA and for normal RbpA function in vivo ([@bib29]). The 10-residue mycobacterial RbpA^BL^ harbors four positively charged residues (K73, K74, K76, R79; [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). In addition to the R79/-13 nt-strand DNA phosphate interaction, RbpA-K74 and K76 are also positioned to make long-range electrostatic interactions (5.4 and 5.5 Å, respectively) with the t-strand DNA phosphates between the −18/--19 and −17/--18 positions, respectively ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Like RbpA-R79, RbpA-K76 is absolutely conserved among RbpA orthologs ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).

The RbpA-R79/DNA interaction is critical for RbpA in vitro function {#s2-3}
-------------------------------------------------------------------

To better understand the roles of the RbpA structural elements in transcription activation, we generated a series of RbpA N-terminal truncations, sequentially deleting the NTT (RbpA^CD-BL-SID^) and the CD (RbpA^BL-SID^; [Figure 2A](#fig2){ref-type="fig"}) and tested their function in abortive initiation assays along with RbpA^R79A^ ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). To expand upon previous *in vitro* studies ([@bib16]; [@bib29]; [@bib53], [@bib54]; [@bib70]), we used σ^A^, RbpA and CarD from *Mtb*/*M. bovis* (the *Mtb* and *M. bovis* factors are identical in sequence; [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}) with recombinant *M. bovis* (*Mbo*) RNAP (99.9% identical in sequence to *Mtb* RNAP; [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}; [@bib15]). We examined two previously characterized *Mtb* promoters: the *vapB10p* antitoxin promoter (VapB; [@bib12]) and the *rrnA*P3 promoter (AP3; [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}; [@bib25]). ChIP-Seq studies in *Msm* indicated that CarD was present at essentially all promoters throughout the genome ([@bib70]), suggesting that CarD and RbpA likely function together. We therefore performed these assays with and without CarD.10.7554/eLife.22520.004Figure 2.Function of RbpA and RbpA derivatives in transcription initiation and cooperativity with CarD.(**A**) Schematic diagram denoting the RbpA derivatives used in subsequent assays. (**B**) The effect of RbpA or RbpA derivatives (denoted at the bottom) on activation of abortive initiation from three different promoters (VapB, AP3, AP3^anti-35^, denoted at the top) with or without CarD. The transcription activity for each promoter was normalized with respect to holo activity on that promoter (holo alone on each promoter was normalized to a value of 1, as shown in lane 1). The error bars denote the standard error from a minimum of three experiments. (**C**) Promoter complex lifetimes measured by abortive initiation on the AP3 promoter. In the top panel, \[^32^P\]-labeled abortive transcript production at times after addition of a large excess of competitor promoter trap DNA ([@bib16]) was monitored by polyacrylamide gel electrophoresis and autoradiography. On the bottom, transcript production was quantified by phosphorimagery and plotted. The lines indicate single-exponential decay curves fit to the data points. The calculated decay half-lives (t~1/2~) are shown to the right of the gel images. (**D**) Structural model showing the *Msm* RbpA/TIC (color coded as in [Figure 1](#fig1){ref-type="fig"}) along with CarD (red), superimposed by aligning the thermus CarD/RPo structure (PDB ID 4XLR; ([@bib4]).**DOI:** [http://dx.doi.org/10.7554/eLife.22520.004](10.7554/eLife.22520.004)10.7554/eLife.22520.005Figure 2---figure supplement 1.Transcription templates and abortive initiation data.(**A**) Sequences of promoter templates used in the transcription experiments (sequences shown only from −60 to +15) for the VapB, AP3, and engineered AP3^anti-35^ promoters. (**B**) Example abortive transcription data used to generate [Figure 2B](#fig2){ref-type="fig"}. \[^32^P\]-labeled abortive transcripts were visualized by polyacrylamide gel electrophoresis and autoradiography. Experiments on each promoter were performed using different specific activities of \[^32^P\] so the band intensities between each promoter are not comparable. (**C**) Abortive transcription reactions directly comparing transcription on AP3 (left) and AP3^anti-35^ (right). Transcription by holo alone on AP3^anti-35^ (lane 5) is more than 10-fold weaker than on AP3 (lane 1).s.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.005](10.7554/eLife.22520.005)

On VapB without CarD, RbpA and RbpA^CD-BL-SID^ activated transcription \~2 fold ([Figure 2B](#fig2){ref-type="fig"}, columns 2--3), suggesting the RbpA^NTT^ does not play a role in activation on this promoter. RbpA^BL-SID^ activated \~3 fold (column 4), while RbpA^R79A^ showed no activation (column 5), suggesting that the BL interaction with DNA is primarily responsible for activation ([Figure 1B](#fig1){ref-type="fig"}). CarD alone increased transcription 3-fold over holo (column 6), but the addition of RbpA increased activation to more than 6-fold (column 7), suggesting the activators work together. The RbpA mutants displayed similar effects without CarD, with the exception that RbpA^R79A^ with CarD repressed transcription compared to CarD alone (column 10).

On AP3 without CarD, RbpA and derivatives behaved similarly as on VapB, but the repressive effect of RbpA^R79A^ was noticeable in the absence of CarD ([Figure 2B](#fig2){ref-type="fig"}, column 14). With CarD, RbpA had little or no additional effect (columns 15--19). Like most promoters in *Mtb*, VapB lacks a −35 element ([@bib12]), while AP3 harbors a nearly consensus −35 element ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). We hypothesized that RbpA may show increased potency on promoters lacking a −35 element. To test this, we generated an AP3 derivative, AP3^anti-35^, containing the least likely base to occur at each position of the −35 element ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}; [@bib66]). Overall, transcription activity on AP3^anti-35^ was decreased more than 10-fold compared to AP3 ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}), and transcription without CarD was barely measurable. However, RbpA in combination with CarD showed a cooperative effect, with a greater than multiplicative effect on transcription activation ([Figure 2B](#fig2){ref-type="fig"}, compare columns 20 and 24 to 25), suggesting the absence of a −35 element accentuates the RbpA/CarD cooperative effect.

In summary, we found that in vitro: (1) Deletion of the RbpA^NTT-CD^ was not deleterious to RbpA activation function, and (2) RbpA-R79 was required for activation function. These results suggest the RbpA^BL-SID^ provides the critical contacts for transcription activation and imply that the role of the SID is to localize the BL to contact the DNA.

Mycobacterial RNAP forms unstable RPo compared to *Eco* when compared on the same promoters, and the main function of CarD appears to be to stabilize RPo ([@bib4]; [@bib16]; [@bib54]). We examined the role of RbpA in stabilizing RPo (with and without CarD) with promoter lifetime assays on AP3 ([@bib16]). RbpA on its own had little to no impact on the RPo half-life (t~1/2~), but the combination of RbpA with CarD had a strongly cooperative effect, extending t~1/2~ more than 2-fold compared to CarD alone ([Figure 2C](#fig2){ref-type="fig"}). With CarD, RbpA^CD-BL-SID^ had a similar effect as RbpA, while RbpA^BL-SID^ extended t~1/2~ to an even greater extent than RbpA. On the other hand, RbpA^R79A^ shortened t~1/2~ significantly below CarD alone, consistent with our findings suggesting that the RbpA^CD^ has a negative effect on transcription.

Our results ([Figure 2](#fig2){ref-type="fig"}) indicate that RbpA and CarD function cooperatively, in agreement with recent studies of [@bib53]. To evaluate whether occupancy of the TIC by RbpA and CarD simultaneously was structurally feasible, we placed CarD in the context of the *Msm* RbpA/TIC by superimposing corresponding Cα coordinates of the thermus CarD/RPo structure (PDB ID 4XLR; [@bib4]). While CarD and RbpA interact with the promoter DNA at or near the upstream part of the −10 element, they do so from opposite sides of the DNA ([Figure 2D](#fig2){ref-type="fig"}) without any steric clash.

RPo formation by mycobacterial RNAP requires three steps {#s2-4}
--------------------------------------------------------

Formation of RPo is a multi-step process ([@bib60]). A sequential mechanism involving at least three steps has been proposed for *Eco* σ^70^-holo based on several decades of studies using the lacUV5 ([@bib8]), λP~R~ ([@bib55]; [@bib60]), T7A1 ([@bib65]), and *rrnB* P1 ([@bib59]) promoters:$$\text{R} + \text{P}\begin{matrix}
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In [Equation 1](#equ1){ref-type="disp-formula"}, R and P represent free RNAP holo and promoter DNA, respectively, and RPo is the final, transcription-competent open complex. RP1 and RP2 represent kinetically-significant intermediates along the pathway of RPo formation. It is thought that RPo formation at most promoters involves similar intermediates, but the significance of different intermediates in each case is dictated by the promoter sequence ([@bib60]). This pathway ([Equation 1](#equ1){ref-type="disp-formula"}) has been studied using mostly approaches that require the RPo reactions to be halted, then probed after the fact ([@bib57]; [@bib61]).

Does [Equation 1](#equ1){ref-type="disp-formula"} describe RPo formation by mycobacterial RNAP? We monitored the kinetic steps of RPo formation by mycobacterial RNAP, and the effects of RbpA and CarD on those steps, using a real-time fluorescence assay first reported by [@bib36]. In this relatively non-perturbing assay, the fluorescence of a Cy3 fluorophore attached to the promoter DNA at the nt-strand +2 position is monitored as RPo formation takes place ([@bib36]; [@bib54], [@bib53]) ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Detecting forward progress in this assay does not depend on the use of competitors, such as heparin. Because interactions between the +2 position of the promoter and RNAP undergo dramatic changes as RPo forms, the environmentally sensitive Cy3 fluorophore ([@bib3]; [@bib74]) is well suited to report on the formation of intermediates in the pathway ([@bib36]; [@bib54], [@bib53]).

Changes in fluorescence as a function of time were monitored after rapid mixing of the Cy3-AP3 promoter construct (Cy3-AP3; [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) with a given protein sample (*Eco* holo, *Mbo* holo, *Mbo* holo+RbpA, *Mbo* holo+CarD, or *Mbo* holo+RbpA+CarD; [Figure 3A--C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}). To separate the binding step (dependent on \[RNAP\]) from subsequent conversions (\[RNAP\]-independent, see [Equation 1](#equ1){ref-type="disp-formula"}), mixing was done for a series of \[RNAP\] (over \~100 fold range; [Supplementary file 3](#SD3-data){ref-type="supplementary-material"}). When factors (RbpA or CarD) were present, they were well above saturating concentrations to ensure high occupancy of RNAP and promoter-bound species ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"}).10.7554/eLife.22520.006Figure 3.Kinetics of RPo formation on the AP3 promoter.(**A**) Plot showing the fluorescence signal vs. time after rapid mixing of *Eco* holo with Cy3-AP3 promoter ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) in a stopped flow fluorimeter. The \[RNAP\] giving rise to each curve is color-coded as shown in the legend. The experimental data are shown as points. The data were fit using the three-step sequential kinetic scheme ([Equation 1](#equ1){ref-type="disp-formula"}), yielding the parameters listed in [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}. The curve fits are shown as solid lines. (**B**) Same as (**A**) but with *Mbo* holo. (**C**) Same as (**A**) but with *Mbo* holo+RbpA+CarD. (**D**) Plot showing the fluorescence signal vs. time after mixing 100 nM *Mbo* holo with 10 nM 2-AP-AP3 promoter ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}) in a stopped flow fluorimeter. The experimental data are shown as points. The data were fit to a single-exponential (solid black line): $F = F_{0} + (F_{max} - F_{0})(1 - e^{k_{app}^{exp}t})$ yielding *k*~app~^exp^ = 0.030 s^−1^. (**E**) Simulation of changes in the populations of P (red), RP1 (orange), RP2 (green), and RPo (blue) under the same conditions as the experiment of panel (**D**). The kinetic parameters used to generate the simulation are from [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}. The data were fit to a single-exponential (thin black line), yielding *k*~app~^sim^ = 0.034 s^−1^. (**F**) (top) The three-step sequential kinetic scheme that best accounts for all of the kinetic data is shown. The steps targeted by the transcription factors RbpA (orange), CarD (green), or RbpACarD together (blue) are denoted. Arrows pointing at a parameter indicate an increase in that parameter in the presence of the factor (compared to *Mbo* holo alone by the fold-amount shown below); the 'T' symbol indicates the factor reduces the parameter. The most important difference between the reference (*Mbo* holo alone) and *Eco* holo (magenta) is also illustrated. RbpA, CarD, and RbpACarD all increase *k*~2~ significantly. CarD also reduces *k*~-3~, as does *Eco* holo to a much greater extent. (bottom) Schematic free energy profile for RPo formation. The black curve represents *Mbo* holo alone. The colored curves illustrate the most important changes induced by the factors (RbpA, orange; CarD, green; RbpACarD, blue; *Eco* holo, magenta). (**G**) Simulations of changes in the populations of P (red), RP1 (orange), RP2 (green), and RPo (blue) when \[P\]~0~ = 1 nM and \[RNAP\]~0~ = 100 nM for *Mbo* holo alone (left) and *Mbo* holo+RbpA+CarD (right). The kinetic parameters used to generate the simulation are listed in [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}. RbpA and CarD together induce a significant increase in *k*~2~, producing a large transient burst of RP2, driving formation of RPo.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.006](10.7554/eLife.22520.006)10.7554/eLife.22520.007Figure 3---figure supplement 1.Cy3 promoters, association and dissociation data, activation energies, and 2-AP promoter.(**A**) Schematics showing the sequences of the Cy3-AP3 and Cy3-VapB promoter constructs, illustrating the attachment points for the Cy3 label by the chemistry shown below. (**B**) Plot showing the fluorescence signal vs. time after rapid mixing of different concentrations of *Mbo* holo+RbpA with 1 nM Cy3-AP3 promoter ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) in a stopped flow fluorimeter. The \[RNAP\] giving rise to each curve is color coded as shown in the legend of [Figure 3A](#fig3){ref-type="fig"}. The experimental data are shown as points. The data were fit using the three-step sequential kinetic scheme ([Equation 1](#equ1){ref-type="disp-formula"}), yielding the parameters listed in [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}. The curve fits are shown as solid lines. (**C**) Same as (**B**) but with *Mbo* holo+CarD. (**D**) *Mbo* holo RPo dissociation experiment. RPo was preformed by incubating 250 nM *Mbo* holo with 1 nM Cy3-AP3 DNA ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), then mixed with 1 µM unlabeled competetive promoter trap DNA ([@bib16]). The fluorescence signal was monitored as a function of time (blue data points). The thin black line shows the simulated experiment calculated fro the kinetic parameters listed in [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}. (**E**) Same as (**D**) but with *Mbo* holo+RbpA. (**F**) The effect of RbpA and CarD on the activation energies of the kinetic steps of RPo formation on the AP3 promoter. The three-step sequential kinetic scheme is illustrated on top, with the rate constants for each step color-coded. Below, the activation energies for the different steps (color-coded) are plotted in a bar graph. (**G**) Sequence of the 2-AP-AP3 construct used in the experiment of [Figure 3D](#fig3){ref-type="fig"}. The introduced 2-AP is shown in magenta.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.007](10.7554/eLife.22520.007)

Qualitative analysis of kinetic data for the AP3 promoter {#s2-5}
---------------------------------------------------------

Some important conclusions can be drawn from examination of the raw fluorescence traces ([Figure 3A--C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}) even without quantitative analysis:

1.  At a given \[RNAP\], *Eco* holo reaches a plateau value about 5-fold faster than *Mbo* holo ([Figure 3A--B](#fig3){ref-type="fig"}).

2.  For *Eco* holo, the fluorescence plateau value is independent of \[RNAP\]; even at the lowest \[RNAP\], *Eco* holo eventually reaches the maximum plateau value ([Figure 3A](#fig3){ref-type="fig"}), On the other hand, the plateau fluorescence for *Mbo* holo depends strongly on \[RNAP\]; lower \[RNAP\] plateaus at a lower fluorescence value ([Figure 3B](#fig3){ref-type="fig"}). These data indicate that *Eco* RNAP converts all of the Cy3-AP3 to RPo in an essentially irreversible reaction, whereas *Mbo* RPo manifests profound reversibility ([@bib16]); *Mbo* RPo coexists with R, P, and intermediates at equilibrium ([Equation 1](#equ1){ref-type="disp-formula"}).

3.  Adding RbpA ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}), CarD ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}), and finally both factors together ([Figure 3C](#fig3){ref-type="fig"}) qualitatively moves the behavior of the *Mbo* system to that of *Eco* holo.

Quantitative analysis of kinetic data for the AP3 promoter {#s2-6}
----------------------------------------------------------

We analyzed the fluorescence progress curves ([Figure 3A--C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}) by globally fitting the data for each concentration series collected on a given day to a kinetic mechanism ([@bib33], [@bib32]). We assumed that the different RNAPs (*Eco* or *Mbo*) or presence of the factors determined the rate constants associated with the mechanism, but did not alter the basic mechanism. Based on previous analyses ([@bib8]; [@bib55]; [@bib59]; [@bib60]; [@bib65]), we considered sequential (linear) kinetic schemes (Appendix). The three-step sequential model best accounted for all of the kinetic data ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}, Appendix), consistent with previous work with *Eco* RNAP.

We can make several observations regarding the validity of our approach and some proposals based on the resulting estimates of the kinetic parameters ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}):

1.  The promoter half-lives calculated using the fitted kinetic parameters ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}; [@bib75]) match the experimentally determined values ([Figure 2C](#fig2){ref-type="fig"}, [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}), providing very strong support for the kinetic analysis.

2.  Structural analysis indicates that RbpA and CarD would be unlikely to influence the Cy3 fluorescence in any of the RNAP/DNA-bound states, and the fluorescence scale factors describing the contribution of each fluorescent species to the total signal (a, b, c, d) refine to similar values for all of the samples ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}). Thus, these values may be physically meaningful. The scale factor for P ('a') refines to the lowest value (\~0.27 ± 0.02) where the fluorophore would be the most solvent exposed and would be expected to have the lowest fluorescence intensity. The scale factor for RP1 ('b') refines to an intermediate value (\~0.45 ± 0.06), suggesting the fluorophore environment is more proteinacous but is still relatively solvent exposed. The scale factors for RP2 ('c') and RPo ('d') refine to the highest values (\~1.2 ± 0.04, \~1.2 ± 0.02, respectively) suggesting that in these states, the fluorophore is relatively shielded from solvent (i.e. inside the RNAP active site cleft).

3.  In addition to a, b, c, d, the value of *k*~3~ also refined to similar values across all of the samples (the standard deviation of the average value across all of the samples is only 26%; [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}). This rate may not be strongly influenced by the identity of the holo (*Eco* or *Mbo*) nor by the presence of RbpA and/or CarD, suggesting that *k*~3~ may be primarily influenced by the properties of the DNA.

4.  For the two most active samples (*Eco* holo and *Mbo* holo+RbpA+CarD), *k*~1~ refines to a maximum value of 1.2 × 10^8^ M^−1^s^−1^, suggesting the possibility that the forward rate for these bimolecular reactions may be diffusion limited. If this is the case, it suggests that the formation of RP1 does not require large conformational changes in the RNAP or the DNA.

For *Mbo* holo and *Mbo* holo+RbpA, the short RPo half-lives ([Figure 2C](#fig2){ref-type="fig"}) made it feasible to monitor RPo dissociation using the fluorescence assay ([Figure 3---figure supplement 1D--E](#fig3s1){ref-type="fig"}). The observed dissociation rates were consistent with the RPo t~1/2~ measured by abortive initiation ([Figure 2C](#fig2){ref-type="fig"}) and calculated from the fitted kinetic constants ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}).

Although these observations all point to the veracity of our kinetic analysis, some of the fitted parameters were not well constrained ([@bib33]). We imposed additional constraints on the data to reduce the degrees of freedom for the fitted parameters. The details of the fitting and validation procedures are described in the Appendix. With these additional constraints, the fits for the parameters were well constrained with the exception of *k*~1~ for *Mbo* holo+RbpA+CarD (Appendix). The final kinetic parameters ([Table 1](#tbl1){ref-type="table"}) were close to the original, unconstrained values (compare [Table 1](#tbl1){ref-type="table"} with [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}).10.7554/eLife.22520.008Table 1.Constrained kinetic parameters on the *Mtb* AP3 promoter. The fluorescence progress curves ([Figure 3A--C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}) were fit according to the 3-step sequential kinetic scheme:$$\text{R} + \text{P}\begin{matrix}
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\rightleftarrows \\
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RbpA and CarD cooperate to affect two distinct steps of RPo formation on the AP3 promoter {#s2-7}
-----------------------------------------------------------------------------------------

The schematic energy profiles for RPo formation ([Figure 3F](#fig3){ref-type="fig"}) help illustrate the following conclusions from our analysis on AP3:

1.  The addition of RbpA alone to *Mbo* holo has a moderate effect on the kinetic parameters, lowering the energy barrier for the RP1 -\> RP2 transition (increasing *k*~2~ \~4 fold), consistent with the small effect of RbpA on transcription activity ([Figure 2B](#fig2){ref-type="fig"}).

2.  The addition of CarD alone also lowers the energy barrier for the RP1 -\> RP2 transition (increasing *k*~2~ \~10 fold).

3.  The effect of RbpA and CarD together on increasing both the rate of formation and the final amount of *Mbo* RPo (compared to *Mbo* holo alone) can be understood by considering fluxes into and out of the intermediate RP2. RbpA and CarD together have a cooperative effect on the RP1 -\> RP2 transition, increasing *k*~2~ \~25 fold, but have little effect on *k*~-2~, increasing K~2~ more than 20-fold ([Table 1](#tbl1){ref-type="table"}). The factors have little influence on *k*~3~, so the net effect is a burst of RP2 in the presence of RbpA and CarD that drives the formation of RPo by mass action ([Figure 3G](#fig3){ref-type="fig"}).

4.  Once formed, RPo is stabilized by CarD (decreasing *k*~-3~ \~6 fold). RbpA has no detectable effect on *k*~-3~ at AP3. However, when RbpA and CarD are present together, *k*~-3~ is reduced \~11 fold.

5.  The main difference between *Eco* and *Mbo* holos is the very large energy barrier for the conversion of RPo -\> RP2 for *Eco* holo ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). This accounts for the essentially irreversible RPo formed by *Eco* holo compared to the relatively unstable RPo of *Mbo* holo observed here and in other studies ([@bib16]).

6.  The rate of formation of RP2 (*k*~2~) for *Mbo* holo+RbpA+CarD is nearly an order of magnitude higher than that of *Eco* holo (9.2 s^−1^ vs 1.2 s^−1^, respectively, [Table 1](#tbl1){ref-type="table"}), indicating that the strong activity of *Eco* holo is attributable almost totally to its very stable RPo (very small *k*~-3~).

DNA opening (RP2 -\> RPo) and closing (RPo -\> RP2) steps are rate-limiting at the AP3 promoter {#s2-8}
-----------------------------------------------------------------------------------------------

Analysis of the activation energies required to traverse the transition states for each kinetic step indicates that for all of the samples on the AP3 promoter, the rate-limiting step (the highest activation energy) in the forward direction is the conversion of RP2 -\> RPo, while the same step is rate-limiting in the reverse direction (RPo -\> RP2; [Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). Consistent with previous analyses, we hypothesized that this rate-limiting step in the forward direction corresponds to the formation of the full transcription bubble ([@bib60]). We tested this hypothesis by monitoring the time-dependent fluorescence from an AP3 promoter derivative harboring 2-aminopurine (2-AP) at the t-strand +2 position ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}) during RPo formation. 2-AP forms a Watson-Crick base pair with thymine in the context of normal B-form DNA ([@bib50]). 2-AP fluorescence is strongly quenched by stacking interactions with neighboring bases, such as in the context of duplex DNA ([@bib31]; [@bib76]), making 2-AP an excellent probe for transcription bubble formation ([@bib44]; [@bib58]). Available data suggest that transcription bubble formation initiates within the −10 element then propagates downstream ([@bib11]; [@bib28]; [@bib44]). We placed 2-AP at the very downstream edge of the transcription bubble so that an increase of 2-AP fluorescence signals full transcription bubble formation, directly preceding or concurrent with RPo formation.

An increase of 2-AP AP3 fluorescence was observed upon the addition of *Mbo* holo ([Figure 3D](#fig3){ref-type="fig"}). We fit the data to a single-exponential to obtain an apparent rate constant, *k*~app~^exp^ = 0.030 s^−1^ ([Figure 3D](#fig3){ref-type="fig"}), nearly identical to the rate of RPo formation simulated from the independently determined kinetic parameters ([Table 1](#tbl1){ref-type="table"}; [Figure 3E](#fig3){ref-type="fig"}; k~app~^sim^ = 0.034 s^−1^), suggesting that the rate-limiting RP2 -\> RPo transition involves the formation of the full transcription bubble.

The −35-less VapB promoter has a very slow RP1 -\> RP2 transition that is rescued by RbpA {#s2-9}
-----------------------------------------------------------------------------------------

It has been noted that RbpA has a more potent effect on transcription of the *Mtb* VapB promoter than on AP3 ([@bib29]). In our assays this is most notable with CarD ([Figure 2B](#fig2){ref-type="fig"}). In order to probe the effects of RbpA and RbpA truncations on transcription in more detail, we generated the Cy3-VapB promoter fragment ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) and monitored RPo formation with the fluorescence assay ([Supplementary file 5](#SD5-data){ref-type="supplementary-material"}). Although both AP3 and VapB are *bona fide Mtb* promoters, VapB is more typical in that it lacks recognizable elements upstream of the −10 element ([@bib12]).

*Mbo* holo forms RPo on VapB about 10 times more slowly than on AP3 ([Figure 4A](#fig4){ref-type="fig"}). The VapB kinetic data were also best fit by the sequential three-step model ([Equation 1](#equ1){ref-type="disp-formula"}). When comparing *Mbo* holo, *Mbo* holo+RbpA, and *Eco* holo on the two promoters, the consistently significant difference in the kinetic parameters is that the RP1 -\> RP2 transition (*k*~2~) is much slower on VapB; the VapB *k*~2~ is 7-fold (*Mbo* holo+RbpA), 47-fold (*Mbo* holo alone), or 230-fold (*Eco* holo) smaller than the AP3 *k*~2~ ([Supplementary file 6](#SD6-data){ref-type="supplementary-material"}; [Figure 4B](#fig4){ref-type="fig"}). Like on AP3 ([Table 1](#tbl1){ref-type="table"}; [Figure 3F](#fig3){ref-type="fig"}), RbpA targets the RP1 -\> RP2 transition, increasing *k*~2~ on VapB by more than 20-fold ([Supplementary file 6](#SD6-data){ref-type="supplementary-material"}; [Figure 4C](#fig4){ref-type="fig"}).10.7554/eLife.22520.009Figure 4.Kinetics of RPo formation on the VapB promoter.(**A**) Plot showing the fluorescence signal vs. time after rapid mixing of *Mbo* holo with Cy3-VapB promoter ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) in a stopped flow fluorimeter. The \[RNAP\] giving rise to each curve is color-coded as shown in the legend. The experimental data are shown as points. The data were fit using the three-step sequential kinetic scheme ([Equation 1](#equ1){ref-type="disp-formula"}), yielding the parameters listed in [Supplementary file 8](#SD8-data){ref-type="supplementary-material"}. The curve fits are shown as solid lines. (**B**) Bar graph comparing the values of *k*~2~ for *Mbo* holo, *Mbo* holo+RbpA, and *Eco* holo on the AP3 promoter (black bars) and the VapB promoter (grey bars). (**C**) Bar graph comparing the values of *k*~2~ for the denoted samples on the VapB promoter. (**D**) The three-step sequential kinetic scheme that best accounts for all of the kinetic data is shown. The steps targeted by the transcription factors RbpA (red), RbpA^CD-BL-SID^ (green), or RbpA^BL-SID^ (blue) are denoted. Arrows pointing at the relevant parameter indicate an increase in that parameter in the presence of the factor (compared to *Mbo* holo alone) by the fold-amount shown below.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.009](10.7554/eLife.22520.009)

Full-length RbpA is essential for normal growth of *Msm* {#s2-10}
--------------------------------------------------------

The increased in vitro activity of RbpA^SID-BL^ ([Figure 2B--C](#fig2){ref-type="fig"}) led us to investigate whether the NTT and CD were required for the essential functions of RbpA in vivo. We constructed an *Msm* strain in which the *rbpA* gene could be efficiently swapped by allelic exchange. As *rbpA* was previously shown to be essential in mycobacteria ([@bib7]; [@bib22]; [@bib74]), we generated a Δ*rbpA* allele in a strain carrying a second copy of *rbpA* integrated at the *attB* chromosomal site conferring streptomycin resistance (MGM6228), which can be efficiently swapped for *rbpA* alleles on an *attB* integrating plasmid conferring kanamycin resistance. In accordance with the essential role of *rbpA*, swapping a vector control plasmid for *rbpA* yielded no transformants, in contrast to efficient marker exchange seen with full length RbpA. We next tested *rbpA* mutant alleles encoding the RbpA derivatives tested in vitro ([Figure 2A](#fig2){ref-type="fig"}). RbpA^CD-BL-SID^, RbpA^BL-SID^, and RbpA^R79A^ all supported viability. Although similar frequencies of allelic replacement were observed for all three alleles, both RbpA^BL-SID^ and RbpA^R79A^ transformants were smaller than those of RbpA^CD-BL-SID^. To quantitate the apparent slow growth phenotype, we determined the doubling times for each of the strains during exponential phase. Whereas RbpA^wt^ doubled at 2.6(±0.16) hr, RbpA^CD-BL-SID^ doubled slightly slower at 3.13(±0.16) hr and RbpA^BL-SID^ and RbpA^R79A^ doubled even more slowly at 4.1(±0.21) hr and 4.6(±0.96) hr, respectively. In addition to growth rate, we monitored cell morphology using light microscopy. RbpA^wt^ and RbpA^CD-BL-SID^ were indistinguishable with regard to cell shape, membrane and nucleoid staining. By contrast, cells expressing RbpA^BL-SID^ showed an array of morphological changes. These included filamentous cells, small cells, aberrant membrane staining, nucleoid condensation, and anucleate ghosts ([Figure 5A](#fig5){ref-type="fig"}). We scored nucleoid morphology as either condensed or diffuse in RbpA^WT^ (n = 208) and RbpA^BL-SID^ (n = 248) and observed that condensed nucleoids were present in 2.4% of RbpA^WT^ cells, whereas 25% of RbpA^BL-SID^ nucleoids were condensed ([Figure 5A](#fig5){ref-type="fig"}). RbpA^R79A^ cells, despite their similarly slow growth rate, did not display morphologic changes compared to WT (data not shown). These findings indicate that, although the essential in vivo function of RbpA can be supplied without the NTT-CD, loss of the CD confers a pleiotropic phenotype of impaired viability and aberrant cell division, likely indicating broad effects on transcription.10.7554/eLife.22520.010Figure 5.In vivo functions of RbpA NTT and CD.(**A**) Morphologic effects of RbpA truncations. *Msm* expressing either RbpA^wt^, RbpA^CD-BL-SID^, or RbpA^BL-SID^ were stained with Hoechst (DNA) and FM 4--64 (membranes), and viewed by both fluorescence illumination and DIC imaging. Representative images are shown. The yellow arrowheads indicate aberrant cell morphology with condensed nucleoid in the RbpA^BL-SID^ strain. The white arrowhead indicates an anucleate filament. Quantitation of nucleoid morphology in WT (n = 208) and RbpA^BL-SID^ (n = 248) cells is graphed below the image as described in the text. Error bars are 99% confidence interval and p\<0.0001 by chi squared test. (**B**) Unsupervised clustering of RNA-seq gene expression data from triplicate RNA samples from cells expressing RbpA^wt^, RbpA^CD-BL-SID^, or RbpA^BL-SID^. The cluster was generated from the 200 genes with the greatest variance between strains. The strains are clustered across the top of the heat map and genes clustered to the left of the heat map. (**C**) Distinct gene expression signatures associated with RbpA domains. Scatterplot of gene expression comparing the log~2~ fold change of RbpA^CD-BL-SID^ (X axis), to RbpA^BL-SID^ (Y axis) each compared to wild type cells. All colored points represent genes with statistically significant differences in RNA level compared to WT (adjusted p\<0.01) with a fold change of \>2 (log~2~ FC of \>1 or \<-1). The genes are classified by color according to their expression pattern as follows: orange (overexpressed in both strains), green (underexpressed in both strains), yellow (overexpressed in BL-SID but not CD-BL-SID), pink (underexpressed in BL-SID but not CD-BL-SID), red (overexpressed in CD-BL-SID but not BL-SID), cyan (underexpressed in CD-BL-SID but not BL-SID). Points with dark outline indicate genes in which the difference in fold change between the two strains is two fold or greater. The single dark blue and purple points represent genes in which the difference between strains is \>2 fold but in opposite direction. See [Supplementary file 7](#SD7-data){ref-type="supplementary-material"} for gene lists corresponding to each color class.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.010](10.7554/eLife.22520.010)

Differential effects of RbpA domains on gene expression in vivo {#s2-11}
---------------------------------------------------------------

The viability of both the RbpA^CD-BL-SID^ and RbpA^BL-SID^ strains afforded an opportunity to test the effects of loss of these RbpA domains on gene expression. We executed RNA-sequencing on the RbpA^CD-BL-SID^ and RbpA^BL-SID^ strains compared to cells with RbpA^wt^. Comparative analyses of the differentially expressed genes between RbpA^wt^/RbpA^CD-BL-SID^ and RbpA^wt^/RbpA^BL-SID^ revealed several patterns. First, despite the complete complementation by RbpA^CD-BL-SID^ for viability, growth, and cell morphology, loss of the NTT had clear effects on gene expression that were distinct from RbpA^BL-SID^, including both overexpressed and underexpressed genes (see red and blue dots, [Figure 5C](#fig5){ref-type="fig"}). These results clearly indicate that the NTT is functional in vivo and may be required for regulation of specific promoters. The RbpA^SID-BL^ strain had an even more globally perturbed pattern of gene expression ([Figure 5B--C](#fig5){ref-type="fig"}), consistent with its pleiotropic phenotype ([Figure 5A](#fig5){ref-type="fig"}). Comparison between the strains indicated a core set of genes either up or downregulated by both RbpA alleles ([Figure 5B--C](#fig5){ref-type="fig"}; orange and green points, [Supplementary file 7](#SD7-data){ref-type="supplementary-material"}). Taken together, these data define distinct in vivo transcriptional functions for the NTT and CD, as well as a core set of genes that are dysregulated when either the NTT or CD is lost.

Discussion {#s3}
==========

CarD and RbpA are key components of mycobacterial TICs. CarD is found at almost all σ^A^ promoters in vivo ([@bib70]), and available evidence points to RbpA being present at all σ^A^ promoters as well. Both factors are essential in the major human pathogen *Mtb*. Our previous analyses of a thermus CarD/TIC showed that CarD stabilizes RPo by the conserved Trp wedging mechanism ([@bib4]; [@bib16]; [@bib70]). Here, we used in vitro and in vivo analyses to examine the mechanism for RbpA and determine how RbpA and CarD function together.

Structure {#s3-1}
---------

The *Msm* RbpA/TIC structure reveals that RbpA participates in a complex network of interactions ([Figure 1](#fig1){ref-type="fig"}). The RbpA^CD^ interacts with the β'zipper, which interacts with σ^A^~3~, both of which contact promoter DNA ([Figure 1B](#fig1){ref-type="fig"}). The RbpA^CD^ also interacts with the ZBD, which interacts with σ^A^~4~, which in turn recognizes the −35 promoter element. The RbpA^SID^ interacts with σ^A^~2~, which interacts with the −10 element. The RbpA/RNAP protein/protein interactions position RbpA^BL^ residue R79 (and to a lesser extend K74 and k76) to interact with the DNA phosphate backbone just upstream of the −10 element ([Figure 1B](#fig1){ref-type="fig"}). Thus, RbpA enhances an intricate network of interactions between the ZBD, the zipper, σ^A^~2~, σ^A^~3~, σ^A^~4~, and promoter DNA.

Pathway of RPo formation {#s3-2}
------------------------

We adapted a previously developed fluorescence assay ([@bib36]; [@bib54]) to monitor the kinetics of RPo formation and to reveal the steps that RbpA and CarD target to stimulate RPo formation ([Figures 3F](#fig3){ref-type="fig"} and [4D](#fig4){ref-type="fig"}). The assay is real-time, relatively non-perturbing ([@bib36]), and highly versatile; it can be used to study the initiation process on virtually any promoter with any bacterial holo, and can be used to study the mechanistic details of extrinsic factors and small molecules that modulate bacterial transcription initiation, which have been estimated to number in the hundreds ([@bib30]).

The kinetic mechanism of RPo formation by *Eco* holo has been extensively studied on four different promoters ([@bib8]; [@bib56]; [@bib59]; [@bib60]; [@bib65]). In each case, a sequential, three-step kinetic mechanism has been proposed ([Equation 1](#equ1){ref-type="disp-formula"}), and this mechanism best explains the kinetic data for mycobacterial RNAP as well.

Crystal structures of the thermus and *Eco* RPo are available ([@bib5]; [@bib79]), but structural information for RP1 and RP2 is limited to footprinting ([@bib60]). These analyses have led to structural models of the kinetically significant intermediates schematized in [Figure 6A](#fig6){ref-type="fig"}. It is useful to discuss our kinetic results in light of these models ([Figure 6A](#fig6){ref-type="fig"}) and explicit structural models of the *Msm* TIC containing RbpA and CarD ([Figure 6B](#fig6){ref-type="fig"}).10.7554/eLife.22520.011Figure 6.Structural transitions during the steps of RPo formation.(**A**) Schematic, cross-sectional views of the RNAP holo (catalytic Mg^2+^, yellow sphere) and the promoter DNA (t-strand, dark blue; nt-strand, blue). RP1 and RP2 represent hypothetical models ([@bib60]). Crystal structures of RPo are available ([@bib5]; [@bib79]). The important functional interaction of RbpA and CarD with the promoter DNA are schematically illustrated (RbpA, purple dot; CarD, red dot), based on the *Msm* RbpA/TIC structure ([Figure 1](#fig1){ref-type="fig"}). (**B**) Explicit structural models of the *Msm* RbpA/CarD/TIC with promoter DNA modeled as in the hypothetical models in (**A**). The RNAP is shown as a transparent molecular surface (color-coded as in [Figure 1](#fig1){ref-type="fig"}). RbpA and the modeled CarD ([Figure 2D](#fig2){ref-type="fig"}) are shown as transparent molecular surfaces with the backbone ribbon also shown. The −35 and −10 elements are colored yellow.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.011](10.7554/eLife.22520.011)

RP1 {#s3-3}
---

Footprinting of the first intermediate (called RP1 here) on several promoters indicates that the DNA is 'closed' (no KMnO~4~ reactivity) and has not entered the active site cleft ([@bib13]; [@bib38]; [@bib56]; [@bib59]; [@bib63]; [@bib65]), leading to models like the one shown for RP1 ([Figure 6A](#fig6){ref-type="fig"}). This early intermediate has often been denoted 'RPc'. Several lines of evidence presented here indicate that RP1 represents an initial encounter complex between holo and duplex promoter DNA. First, the rate of forming RP1 appears diffusion-limited (\~10^8^ M^−1^s^−1^) for the two most active samples (*Eco* holo and *Mbo* holo+RbpA+CarD), ruling out large conformational changes in the RNAP or the DNA. Second, neither CarD nor RbpA affect *k*~1~, *k*~-1~, or K~1~ significantly on either AP3 or VapB ([Table 1](#tbl1){ref-type="table"}, [Supplementary file 8](#SD8-data){ref-type="supplementary-material"}). Third, values of *k*~1~, *k*~-1~, and K~1~ for AP3 (with a nearly consensus −35 element; [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}) and for VapB (lacking a -35 element; [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}) do not differ, suggesting that sequence-specific readout of the of the −35 element by σ~4~ occurs in subsequent steps ([@bib9]).

The −10 element sequence is recognized only in its single-stranded form ([@bib20], but RP1 DNA is closed. How is initial promoter recognition achieved if DNA sequence-specific interactions upstream of the −10 element are not critical for formation of RP1? Non-sequence-specific protein/DNA interactions presumably orient holo with respect to the duplex DNA in a way that promotes subsequent steps leading to RPo formation. In particular, we suggest that in RP1, an important component of promoter recognition by holo may be mediated through distinct conformational characteristics of promoter DNA ([@bib21]). Indeed, the chemical probe 1,10-phenanthroline copper reacts uniquely with the −10 element region of several promoters in the absence of any proteins, indicating special conformational characteristics ([@bib68]; [@bib69]).

While [@bib54] suggested that CarD destabilizes an initial, RPc-like complex on AP3, we find that CarD has no effect on the stability of RP1 and stabilizes both RP2 and RPo ([Figure 3F](#fig3){ref-type="fig"}). We suggest that their proposal is inconsistent with our results due the following: The inherent difficulty of trying to deduce mechanisms from multi-exponential fits to the data, working at non-saturating concentrations of CarD where mixed populations of CarD bound and unbound species without distinct fluorescent signals exist, and finally interpreting these results within the framework of a two-step kinetic mechanism instead of the three-step mechanism shown here to be necessary to account for the data (Appendix). This latter simplification can lead to erroneous interpretations ([@bib75]). Our analysis yielded estimates for the forward and reverse rate constants for the three kinetic steps ([Table 1](#tbl1){ref-type="table"}). The promoter half-lives calculated from these rate constants on the AP3 promoter matched the independently, experimentally determined values ([Figure 2C](#fig2){ref-type="fig"}, [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}), supporting the validity of our approach.

RP2 {#s3-4}
---

The conversion of RP1 to the next significant intermediate extends protection of DNA from cleavage reagents further downstream to +10 and beyond ([@bib59]; [@bib60]; [@bib65]). Models for this intermediate posit a sharp bend of the DNA at the −10 element (RP2, [Figure 6A](#fig6){ref-type="fig"}), positioning the downstream duplex DNA across the entrance to the RNAP active site cleft ([@bib60]). While this intermediate appears closed on some promoters ([@bib59]; [@bib60]), partial transcription bubble formation has been observed on T7A1 ([@bib56]). Limited transcription bubble formation could be hidden from KMnO~4~ footprinting because of interactions of unstacked bases with the RNAP ([@bib5]), and current models suggest that at least one base (the highly conserved −11A of the −10 element nt-strand; [@bib20]) is flipped out of the DNA duplex in this intermediate, facilitating the kink in the DNA ([@bib60]; [@bib77]); [Figure 6A](#fig6){ref-type="fig"}).

While the −35 element does not appear to be important for the formation of RP1, it is very important for the progression of RP1 to RP2. Indeed the most striking kinetic difference between VapB (lacking a −35 element) and AP3 (with a −35 element) is in the RP1 -\> RP2 transition (*k*~2~, *k*~-2~, K~2~; [Supplementary file 6](#SD6-data){ref-type="supplementary-material"}): the VapB *k*~2~ is reduced nearly 50-fold (*Mbo* holo) and 230-fold (*Eco* holo) compared to AP3. The simple interpretation of these large effects is that DNA sequence-specific, σ~4~/−35 element interactions ([@bib9]) are established as RP2 forms, providing part of the favorable binding free energy to drive the RP1 -\> RP2 transition. Previous work has shown that stabilizing upstream σ~4~/DNA interactions can stimulate isomerization to RPo ([@bib18]).

Interactions upstream of the −10 element may play a key structural role in facilitating the −11/--12 kink in the DNA ([Figure 6](#fig6){ref-type="fig"}) by anchoring the lateral position of RNAP on the promoter DNA and/or by constraining the twist of the DNA. These upstream interactions may effectively position the −10 element with respect to the pocket on σ^A^~2~ that captures the flipped out −11A ([@bib20]). On both AP3 and VapB, RbpA affects only *k*~2~, with the largest effect on VapB ([Table 1](#tbl1){ref-type="table"}; [Supplementary file 8](#SD8-data){ref-type="supplementary-material"}; [Figures 3F](#fig3){ref-type="fig"} and [4D](#fig4){ref-type="fig"}), suggesting that the interaction of RbpA-R79 with the nt-strand −13 phosphate ([Figure 1B](#fig1){ref-type="fig"}) fulfills this anchoring role when σ~4~/−35 element interactions cannot form. We note the majority of *Mtb* promoters appear to lack a −35 region ([@bib12]), suggesting why, in part, RpbA is required for cell viability.

In the case of *Mbo* holo on AP3, CarD alone stimulates *k*~2~ \~10 fold. In the model of RP1, the position of the CarD-CTD clashes with duplex DNA ([Figure 6A](#fig6){ref-type="fig"}; [@bib70]; [@bib4]). Favorable interactions of the CarD-CTD with promoter DNA require widening of the minor groove at the upstream edge of the −10 element (from about −14 to −10), which is coupled with initial opening of the −10 element ([@bib4]) and bending of the DNA, sending it towards the active site channel ([Figure 6B](#fig6){ref-type="fig"}). While flexibility between the CarD-RID (interacting with the RNAP β-lobe 1) and the CarD-CTD ([@bib27]) combined with RNAP clamp opening may alleviate any clash in RP1, the RP1 model illustrates how the favored position of the CarD-CTD could drive RP2 formation by stabilizing the initial formation of the upstream duplex/single stranded junction ([Figure 6B](#fig6){ref-type="fig"}).

The 2-AP experiments ([Figure 3D--E](#fig3){ref-type="fig"}) indicate that opening of the downstream edge of the transcription bubble does not occur at a rate comparable to the formation of RP2 but at the slower rate of RPo formation. We conclude that *Mbo* holo on AP3 forms the transcription bubble in a two-stage process, with initial opening of the −10 element in RP2. Further downstream opening then creates the transcription bubble in RPo ([Figure 6](#fig6){ref-type="fig"}).

CarD and RbpA together have a cooperative effect on the RP1 -\> RP2 transition, and both factors interact with the promoter DNA at or near the upstream edge of the −10 element ([Figures 2D](#fig2){ref-type="fig"} and [6B](#fig6){ref-type="fig"}). A CarD/RbpA protein/protein interaction in the context of the TIC could explain this cooperativity, but this seems unlikely on the basis of the structural modeling ([Figure 2D](#fig2){ref-type="fig"}). The RbpA^NTT^ is not accounted for in our structure, but deletion of the NTT (and the NTT-CD) does not abrogate the CarD/RbpA cooperativity ([Figure 2B](#fig2){ref-type="fig"}). Rather, RbpA and CarD affect the same step (RP1 -\> RP2 transition), but do so non-competitively and in different ways. In this scheme, initial opening of the −10 element and DNA bending are coupled. Through its anchoring role, RbpA stimulates formation of RP2 through facilitating bending, which is coupled with initial opening of the −10 element, facilitating CarD function. Through its wedging role, CarD stabilizes the initial −10 opening, which is coupled to bending, facilitating RbpA function.

RPo {#s3-5}
---

The RP2 -\> RPo transition opens the DNA duplex downstream to the start site ([Figure 3D](#fig3){ref-type="fig"}) and loads the t-strand DNA into the RNAP active site ([Figure 6C](#fig6){ref-type="fig"}). The step involving full transcription bubble formation on λP~R~ is rate-limiting in the forward direction, and the same step is rate-limiting in the reverse direction ([@bib60]). On *rrnB* P1, stabilization of the full transcription bubble requires ATP and CTP, the first two nucleotides of the transcript ([@bib59]), indicating that expansion of the transcription bubble downstream to the start site is energetically difficult in this case as well. On AP3, opening of the full transcription bubble occurs during the RP2 -\> RPo transition ([Figure 3D--E](#fig3){ref-type="fig"}), and this transition is rate-limiting in both directions ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}).

RbpA function in vivo {#s3-6}
---------------------

Our analyses of RbpA function in vivo confirm that RbpA, like CarD, is essential for viability. Loss of the NTT or NTT-CD, despite relatively minor biochemical effects in vitro on the tested promoters ([Figures 2B--C](#fig2){ref-type="fig"} and [4C--D](#fig4){ref-type="fig"}; [Supplementary file 8](#SD8-data){ref-type="supplementary-material"}), has clear effects on gene expression in vivo ([Figure 5B--C](#fig5){ref-type="fig"}). Although all of these effects cannot be attributed directly to RbpA function at present, some of the changes are likely direct effects of the RbpA truncations at specific promoters. Similarly, we detected a core set of genes that are dysregulated in both RbpA alleles, suggesting that some of these may be direct RbpA targets, raising the possibility that the truncated RbpA segments may interact with additional, as yet unidentified, transcription regulators.

In our in vitro analyses, RbpA^R79A^ by itself appeared to have lost all RbpA function in activating transcription and counteracted the activity of CarD when both factors were present ([Figure 2B](#fig2){ref-type="fig"}, [Supplementary file 8](#SD8-data){ref-type="supplementary-material"}). Therefore, our finding that RbpA^R79A^ supported viability was surprising. However, our results clearly show that the in vivo role of RbpA is very complex ([Figure 5](#fig5){ref-type="fig"}), and in this work we have only examined two *bona fide* mycobacterial promoters, AP3 and VapB. It seems likely that other promoters are regulated by RbpA^R79A^*in vivo*, possibly through the action of additional conserved basic residues on the BL such as K76 ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Motif searches, direct assays of RbpA genome wide promoter binding, and identification of potential protein binding partners will be needed to begin to unravel the specific RbpA regulated gene sets and/or interaction partners that mediate its essential function in vivo and the rules that may determine the differential effects of RbpA at specific promoters.

Conclusions {#s3-7}
-----------

The work presented here provides an unprecedented structural framework for understanding mycobacterial transcription. With our in vitro functional analysis and in combination with our previous analyses of CarD structure and function ([@bib4]; [@bib16]; [@bib70]), we propose the following model ([Figure 6B](#fig6){ref-type="fig"}): RbpA-R79 interaction with duplex DNA upstream of the −10 provides an anchoring role that facilitates the bending (RP2) and subsequent formation of the full transcription bubble (RPo). Initial distortions of the DNA in RP2 are compatible with CarD to wedge its conserved Trp residue into the splayed minor groove, which not only contributes to formation of the RP2 intermediate, but also serves as a barrier for bubble collapse once RPo has formed. Our in vivo analyses point to a complex role for the various structural elements of RbpA in promoter specific regulation and possible interactions with additional factors. The role of RbpA in facilitating the formation of RP2 is particularly important at promoters lacking sequence elements upstream of the −10 element, which represents the majority of *Mtb* promoters ([@bib12]), possibly explaining why RbpA is essential and spotlighting the importance of studying a diversity of organisms in efforts to characterize 'conserved' processes such as transcription.

Materials and methods {#s4}
=====================

Standard procedures were used to manipulate recombinant DNA and to transform *Eco. Msm* strains were derivatives of *mc^2^155* ([@bib67]). *Msm* was transformed by electroporation (2500 V, 2.5 µF, 1000 Ω). All *Msm* strains were cultured in Lbsmeg (LB with 0.5% glycerol, 0.5% dextrose, and 0.05% Tween~80~). Antibiotic concentrations used for selection of *Msm* strains were as follows: kanamycin 20 µg/ml, hygromycin 50 µg/ml, streptomycin 20 µg/ml. All *Msm* strains, plasmids with relevant features, and primers used in generating the *Msm* strains are listed in [Supplementary files 9](#SD9-data){ref-type="supplementary-material"} and [10](#SD10-data){ref-type="supplementary-material"}.

Protein expression and purification {#s4-1}
-----------------------------------

### Msm *RbpA/σ^A^* {#s4-1-1}

*Msm* pET-SUMO σ^A^ (received from C. Stallings) and pet21C*-*RbpA (cloned from *Msm* mc2155 genomic DNA) were co-transformed into BL21(DE3) *Eco* cells. Protein expression was induced at 30°C for 3 hr with 0.5 mM IPTG at O.D.~600nm~ = 0.6 and purified by Ni^2+^-affinity chromatography (HiTrap IMAC HP, GE Healthcare Life Sciences, Pittsburgh, PA) as described ([@bib29]). Following elution, the complex was dialyzed overnight into 20 mM Tris-HCl, pH 8, 0.5 M NaCl, 5 mM imidazole, 5% (v/v) glycerol, 0.5 mM β-mercaptoethanol, and the His~10~-SUMO tag was cleaved by incubation with ULP1 protease overnight at a ratio of 1/25 (ULP1 mass/cleavage target mass). The cleaved complex was loaded onto a second Ni^2+^-affinity column and was retrieved from the flow-through and low-imidazole washes. The complex was loaded directly on a size exclusion column (SuperDex-200 16/16, GE Healthcare Life Sciences) equilibrated with 20 mM Tris-HCl, pH 8, 0.5 M NaCl, 5% glycerol (v/v), 1 mM DTT, 1 mM EDTA. The sample was concentrated to 15 mg/ml by centrifugal filtration and stored at −80°C.

### Msm *RNAP* -- rpoC-ppx-His~10~*construction* {#s4-1-2}

To construct an *Msm* strain for endogenous RNAP purification, we inserted a PreScission Protease (ppx; GE Healthcare Life Sciences) and His~10~-tag (ppx-His~10~-tag) at the 3' end of the *rpoC* gene by single crossover integration of pAJF527, which carries 554 bp of the 3' end of *rpoC* fused to the ppx cleavage sequence (LEVLFQGP) and His~10~ affinity tag. pAJF527 was transformed into MC2155 and transformants were selected with hygromycin. Transformants were screened for integration at *rpoC* by PCR amplification using primers that anneal to 79 bp upstream of the 3' flank (oAF799) and within the integrating vector downstream of the His~10~-tag (oAF021). RNAP β'-ppx-His~10~ expression was confirmed by immunoblot using HisProbe (ThermoScientific Pierce, Waltham, MA), which detected a protein species at approximately 150 kDa. The resulting strain (MGM6029) showed no growth defects under standard laboratory conditions, indicating that the tagged RNAP β' subunit is functional (as it is the only copy in the cell).

### *Msm* RNAP purification {#s4-1-3}

Endogenous *Msm* RNAP was purified from the *Msm* mc2155 strain expressing a native chromosomal copy of *rpoC* with a C-terminal ppx-His~10~-tag. *Msm* cells were grown at the Bioexpression and Fermentation Facility at the University of Georgia. Cells were lysed by continuous flow French press (Avestin) in 50 mM Tris-HCl, pH 8, 1 mM EDTA, 5% (v/v) glycerol, 5 mM DTT, 1 mM protease inhibitor cocktail, 1 mM phenylmethylsulfonyl fluoride, and core RNAP was precipitated from the cleared lysate by polyethyleneimine (PEI) precipation (0.35%). The PEI pellet was washed four times with 10 mM Tris-HCl, pH 8, 0.5 M NaCl, 0.1 mM EDTA, 5 mM DTT, 5% (v/v) glycerol, then eluted four times with the same buffer but with 1 M NaCl. Protein was precipitated overnight with 35% (w/v) ammonium sulfate and resuspended in 20 mM Tris-HCl, pH 8, 5% (v/v) glycerol, 1 M NaCl, 1 mM β-mercaptoethanol. Protein was loaded on a Ni^2+^-affinity column (HiTrap IMAC HP, GE Healthcare Life Sciences) and eluted in 20 mM Tris-HCl, pH 8, 5% (v/v) glycerol, 0.5 M NaCl, 0.25 M imidazole. Protein was diluted in 10 mM Tris-HCl, pH 8, 5% (v/v) glycerol, 0.1 mM EDTA, 5 mM DTT to a final salt concentration of 0.1 M NaCl, loaded on a Biorex (BioRad, Hercules, CA) ion exchange column, and eluted with a gradient from 0.1 M -- 0.8 M NaCl. A 5X molar excess of the purified *Msm* RbpA/σ^A^ complex was added to the RNAP and the resulting complex was purified by size exclusion chromatography (Superdex-200, GE Healthcare Life Sciences) in 20 mM Tris-HCl, pH 8, 5% (v/v) glycerol, 0.5 M NaCl, 0.25 M imidazole. The purified complex was dialyzed into 20 mM Tris-HCl, pH 8, 100 mM K-glutamate, 10 mM MgCl~2~, 1 mM DTT, concentrated by centrifugal filtration to \~15 mg/ml, and stored at −80°C.

### Eco/Mtb/Mbo *proteins* {#s4-1-4}

*Eco* core RNAP, *Eco* σ^70^, *Mtb/Mbo* σ^A^, RbpA, RbpA^R79A^, CarD, and recombinant *Mbo* core RNAP were expressed and purified as described ([@bib16]; [@bib29]). *Mtb/Mbo* RbpA truncations ([Figure 2A](#fig2){ref-type="fig"}; [@bib29]) were expressed in BL21(DE3) *Eco* cells from a pET-SUMO vector and purified using the same procedure as for RbpA.

Crystallization of *Msm* RbpA/TIC {#s4-2}
---------------------------------

The upstream-fork promoter fragment (T10; [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) was assembled from synthetic oligos (Integrated DNA Technologies, Coralville, IA) by annealing in 10 mM Tris-HCl, pH 8, 1 mM EDTA, 0.2 M NaCl. Aliquots were stored at −20°C. The purified *Msm* RbpA/σ^A^-holo was mixed in a 1:1 molar ratio with annealed T10 upstream fork DNA to generate the *Msm* RbpA/TIC. Crystals were grown by hanging drop vapor diffusion by mixing 1 µL of *Msm* RbpA/TIC solution (11 mg/mL protein) with 1 µL of crystallization solution \[0.1 M Bis-Tris, pH 6.0, 0.2 M LiSO~4~, 16% (w/v) polyethylene glycol 3350, 2.5% (v/v) ethylene glycol\] and incubating over a well containing crystallization solution at 22°C. Crystals grew to full size in approximately 10 days, with the largest crystals (very rare) having dimensions \~200 × 200 x 1000 μm. The crystals were cryo-protected by step-wise transfer (three steps) into 0.1 M Bis-Tris, pH 6.0, 0.2 M LiSO~4~, 22% (w/v) polyethylene glycol 3350, 20% (v/v) ethylene glycol and flash frozen by plunging into liquid nitrogen.

Data collection, structure determination, and refinement {#s4-3}
--------------------------------------------------------

X-ray diffraction data were collected at the Argonne National Laboratory Advanced Photon Source (APS) NE-CAT beamline 24-ID-E. Structural biology software was accessed through the SBGrid consortium ([@bib47]). Data were integrated and scaled using HKL2000 ([@bib51]).

An initial electron density map was calculated by molecular replacement using Phaser ([@bib46]) from a starting model generated from *Thermus aquaticus* RNAP holo (PDB ID 4XLP; [@bib5]) but with σ^A^~2~ deleted and replaced with *Mtb* σ^A^~2~ (from PDB ID 4X8K; [@bib29]). One RbpA/TIC complex was clearly identified in the asymmetric unit. The model was first improved using rigid body refinement of 20 individual mobile domains using PHENIX ([@bib1]). The resulting model was improved by iterative cycles of manual building with COOT ([@bib19]) and refinement with PHENIX ([@bib1]). The PDBePISA server (<http://www.ebi.ac.uk/pdbe/pisa/>) was used to calculate intermolecular buried surface areas.

In vitro transcription assays {#s4-4}
-----------------------------

In vitro abortive initiation transcription assays and promoter lifetime assays ([Figure 2](#fig2){ref-type="fig"}) were performed at 37°C as described ([@bib16]). AP3^anti-35^ promoter was prepared using PCR amplification on a synthesized template (Integrated DNA Technologies). Assays with the AP3^anti-35^ promoter were performed in KGlu assay buffer (10 mM Tris-HCl, pH 8.0, 100 mM K-glutamate, 10 mM MgCl~2~, 0.1 mM EDTA, 0.1 mM DTT, 50 μg/mL BSA). All other assays were performed in KCl assay buffer (10 mM Tris-HCl, pH 8.0, 50 mM KCl, 10 mM MgCl~2~, 0.1 mM EDTA, 0.1 mM DTT, 50 μg-/mL BSA).

*Mbo* core (50 nM) was incubated with σ^A^ (250 nM) for 5 min at 37°C to form holo and, when used, CarD and or RbpA or RbpA derivatives (all 2 μM) were added and incubated for an additional 5 min. DNA template (10 nM) was then added and incubated with the protein mixture for 15 min to form RPo. Abortive initiation assays were initiated on VapB with ApU dinucleotide primer (250 μM; Trilink Biotechnologies, San Diego, CA), \[α-^32^P\]GTP (1.25 μCi; Perkin Elmer Life Sciences, Waltham, MA), and unlabeled GTP (50 μM; GE Healthcare Life Sciences). Abortive transcription for abortive initiation and promoter lifetime assays were initiated on AP3 with GpU dinucleotide primer (250 μM; Trilink Biotechnologies), \[α-^32^P\]UTP (1.25 μCi; Perkin Elmer Life Sciences), and unlabeled UTP (50 μM; GE Healthcare Life Sciences). Competitor DNA for the promoter lifetime assays was full-con bubble promoter trap DNA ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} from [@bib16]). Transcription products were visualized by polyacrylamide gel electrophoresis (23%) followed by phosphorimagery and quantitation using Image J.

Stopped-flow kinetics with Cy3-DNA {#s4-5}
----------------------------------

### Preparation of DNA. {#s4-5-1}

Cy3-AP3 promoter DNA ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) was prepared using Cy3-amido-dT modified DNA (Cy3-AP3-DNA1):

^5'^CATCTATGGATGACCGAACCTGGTCTTGACTCCATTGCCGGATTTGTATTAGACTGGCAGGGTTG/ICY3N/TG^3'^ from Integrated DNA Technologies. Cy3-AP3-DNA1 (0.25 μM) was mixed with AP3-DNA2 (0.25 μM; Integrated DNA Technologies):

^5'^TTCTGAGTTCGGCATGGGGTCAGGTGGGACCCAAGCTTCCGCTTCGGGGCAACCCTGCCAGTCTAATAC^3\'^

The annealed oligos were extended using *Taq* DNA polymerase with 20 cycles (30 s each) of heating to 95°C, annealing at 48°C, and extending at 72°C. The resulting product was visualized on a non-denaturing 6% polyacrylamide gel stained with Gel Red (Biotium, Fremont, CA) to verify a single product, and then purified using PCR clean up (Qiagen, Hilden, Germany).

Cy3-VapB promoter DNA ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) was prepared as above but with the following starting synthetic oligos (Integrated DNA Technologies):

Cy3-VapB-DNA1:

^5'^GGCTGAATCGCCGCCCGCCGCGGTGCCGCCCGGGCCGCACATTGTGATGTATGATATGGTGTA/ICY3N/G^3'^

VapB-DNA2:

^5'^CGTGTAACACTACATACTATACCACATACTTCGCCTGGTTGTAGATGGAGCTGCTCCTCGTCTGCCGTTCGGAGCTGTT^3'^

### Stopped-flow assays -- forward kinetics {#s4-5-2}

To monitor the kinetics of RPo formation, proteins (RNAP and transcription factors if present, see [Supplementary files 3](#SD3-data){ref-type="supplementary-material"} and [5](#SD5-data){ref-type="supplementary-material"} for assay conditions) were loaded in one syringe of a stopped-flow instrument (AutoSF-120, KinTek Corporation, Snowshoe, PA) and Cy3-DNA was loaded into the other. After rapid mixing at 37°C, the final solution conditions were 10 mM Tris-HCl, pH 8, 50 mM K-glutamate, 20 mM NaCl, 10 mM MgCl~2~, 1 mM DTT. Cy3 fluorescence emission was monitored in real time with a 586/20 single-band bandpass filter (Semrock, Rochester, NY) with excitation at 515 nM.

### Stopped-flow assays -- reverse kinetics {#s4-5-3}

To monitor the kinetics of RPo dissociation for *Mbo* holo and *Mbo* holo+RbpA, RPo was preformed on Cy3-AP3 DNA by incubating at 37°C for 30 min prior to loading into one syringe of the stopped-flow instrument. The other syringe was loaded with full-con bubble promoter trap DNA ([@bib16]). After rapid mixing at 37°C, the final solution conditions were *Mbo* holo (250 nM), RbpA (when present, 5 μM), Cy3-AP3 DNA (1 nM), full-con bubble promoter trap DNA (1 µM). Cy3 fluorescence emission was monitored in real time as above. For each sample, three independent 'shots' were averaged together ([Figure 3---figure supplement 1D--F](#fig3s1){ref-type="fig"}).

### Stopped-flow assays with 2-AP-AP3 DNA {#s4-5-4}

The 2-AP-AP3 (bottom strand) DNA ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}) was obtained from Trilink Biotechnologies, 2-AP-AP3 (top strand) was obtained from Integrated DNA Technologies. The two synthetic oligos were annealed using the same procedure described above. To monitor the kinetics of RPo formation, *Mbo* holo was loaded in one syringe of the stopped-flow instrument, and 2-AP-AP3 DNA was loaded in the other. After rapid mixing at 37°C, the final solution conditions were *Mbo* holo (250 nM), 2-AP-AP3 DNA (10 nM). The 2-AP fluorescence emission was monitored in real time with a 357/44 nm BrightLine single-band bandpass filter (Semrock) with excitation at 315 nm. The curve shown in [Figure 3D](#fig3){ref-type="fig"} was the result of averaging six 'shots'.

Data analysis is described in the text and in the Appendix.

Δ*rbpA* construction {#s4-6}
--------------------

Gene deletion was made by homologous recombination and double negative selection ([@bib6]). Briefly, approximately 500 bp upstream of the coding sequence and 500 bp downstream of the coding sequence of *rbpA* (MSmeg_3858) were cloned into the suicide plasmid pAJF067 containing a hygromycin cassette for positive selection of integration and two markers for negative selection, *sacB* and *galK*. After transformation of *Msm* with this plasmid, hygromycin resistant colonies resulting from a single crossover event were verified as intermediates by PCR. A merodiploid was then generated by adding a second copy of *rbpA* at *attB*(L5) by transformation with pAJF685 and subsequently a second crossover was selected to generate Δ*rbpA* by counterselecting on sucrose and 2-deoxygalactose containing agar media after passaging in the absence of hygromycin. Deletion mutants were verified by PCR. To assess if *rbpA* was essential, allele swapping was performed for the *attB* integrated copy of *rbpA* using marker exchange for either pMV306kn (empty vector), pAJF672 (encoding full length RbpA), pAJF679 (RbpA(28-114aa) or pAJF680 (RbpA(72-114aa). No transformants were recovered from the empty vector control transformations, confirming the essentiality of *rbpA*.

RbpA growth curves {#s4-7}
------------------

All growth curves were performed in LBsmeg (no antibiotics) at 37°C. Triplicate cultures were grown overnight to mid logarithmic phase and then diluted back. After 15 hr of growth when cultures reached an OD600 of 0.1, measurements were taken every 2 hr until the cells reached an OD600 of 0.6. Doubling times were then calculated.

Microscopy {#s4-8}
----------

All images were acquired using a Zeiss (Oberkochen, Germany) Axio Observer Z1 microscope equipped with, Colibri.2 and Illuminator HXP 120 C light sources, a Hamamatsu (Hamamatsu, Japan) ORCA-Flash4.0 CMOS Camera and a Plan-Apochromat 100×/1.4 oil DIC objective. Zeiss Zen software was used for acquisition and image export. The following filter sets and light sources were used for imaging: Hoechst 33342 (49 HE, HXP 120 C) and FM 4--64 (20, HXP 120 C). For cell staining 100 µl of culture was used. A final concentration of 1 µg/ml FM 4--64 (Invitrogen, Carlsbad, CA) and/or 10 µg/ml Hoechst 33342 (Invitrogen) was added. Cells were collected by centrifugation at 5000 g for 1 min and resuspended in 50 µl of media. For time-lapse microscopy, cells were added to a 1.5% low melting point agarose PBS pad. Agarose was heated to 65°C and poured into a 17 × 28 mm geneframe (Thermoscientific, AB-0578) adhered to a 25 × 75 mm glass slide. A second slide was pressed down on top and the set-up was allowed to cool at room temperature for 10 min. 2--3 µl of *Msm* culture was added to the pad and a No. 1.5 24 × 40 mm coverglass was sealed to the geneframe.

RNA purification {#s4-9}
----------------

Bacterial culture (50 mL) normalized to an OD~600~ of 0.4 was cooled to 4°C and harvested by centrifugation. Pellets were resuspended in RNALater (Invitrogen) and stored overnight at 4°C. Pellets collected by centrifugation were washed in 1 ml of 10 mM Tris-HCl, pH 8.0. Pellets were then resuspended in 100 µl TE~80~ with 1 mg/ml lysozyme and disrupted by bead beating with a FastPrep120 2 times at 5.0 m/s for 25 s. This lysate was used for RNA purification with a GeneJet RNA purification kit (Thermoscientific) following the manufacturer\'s protocol. RNA was eluted in 85 µl elution buffer and then treated with DNase I (Thermoscientific) for 30 min at 37°C. GeneJet purification columns were used to clean RNA from DNaseI reactions.

RNA sequencing and data analysis {#s4-10}
--------------------------------

Sample libraries were prepared for RNA-seq using the Ribo-Zero Magnetic Bacterial kit (Epicentre, Madison, WI) in connection with TruSeq Stranded Total RNA kit (Illumina, San Diego, CA). Paired-end reads (10--20 × 10^6^) were obtained for each sample replicate on an Illumina HiSeq 2500. Post-run demultiplexing and adapter removal were performed and fastq files were inspected using fastqc ([@bib2]). Trimmed fastq files were then aligned to the reference genome (M. smegmatis MC^2^155; NC_008596.1) using bwa mem ([@bib41]). Bam files were sorted and merged using samtools ([@bib42]) and gene counts were obtained using featureCounts from the Bioconductor Rsubread package ([@bib43]). Differentially expressed genes were identified using the DESeq2 R package ([@bib45]) and subsequent analysis of gene expression was performed in R ([@bib37]; [@bib52]).

Accession numbers {#s4-11}
-----------------

The X-ray crystallographic coordinates and structure factor file have been deposited in the Protein Data Bank with accession ID 5TW1. The RNA-seq data have been deposited in the Gene Expression Omnibus (GEO) database with accession number GSE89773.
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Fay A,Glickman MS,2016,Gene expression profile of M. smegmatis expressing RbpA truncations,<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89773>,Publicly available at NCBI Gene Expression Omnibus (accession no: GSE89773)

The following previously published datasets were used:

Hubin EA,Flack JE,Tabib-Salazar A,Paget MS,Darst SA,Campbell EA,2014,*Mycobacterium tuberculosis* RbpA-SID in complex with SigmaA domain 2,<http://www.rcsb.org/pdb/explore/explore.do?structureId=4X8K>,Publicly available at Protein Data Bank (accession no: 4X8K)

Bortoluzzi A,Muskett FW,Waters LC,Addis PW,Rieck B,Munder T,Schleier S,Forti F,Ghisotti D,Carr MD,O\'Hare HM,2013,*Mycobacterium tuberculosis* RNA polymerase binding protein A (RbpA) and its interactions with sigma factors,<http://www.rcsb.org/pdb/explore/explore.do?structureId=2M4V>,Publicly available at Protein Data Bank (accession no: 2M4V)

Bae B,Darst SA,2015,Crystal structure of *T.aquaticus* transcription initiation complex with CarD containing bubble promoter and RNA,<http://www.rcsb.org/pdb/explore/explore.do?structureId=4XLR>,Publicly available at Protein Data Bank (accession no: 4XLR)

Bae B,Darst SA,2015,Crystal structure of *T.aquaticus* transcription initiation complex containing upstream fork promoter,<http://www.rcsb.org/pdb/explore/explore.do?structureId=4XLP>,Publicly available at Protein Data Bank (accession no: 4XLP)

Introduction {#s45}
============

In this Appendix we describe details of the kinetic analyses validating the results and conclusions presented in the main manuscript. First, we establish that the minimal kinetic scheme required to describe our data is the 3-step sequential kinetic scheme ([Appendix 1---figure 1](#fig7){ref-type="fig"}). Second, we present the results of confidence contour analysis ('FitSpace' analysis within the context of KinTek Global Kinetic Explorer; [@bib32]) to validate that the parameter estimation ([Table 1](#tbl1){ref-type="table"}, main manuscript) is well constrained.10.7554/eLife.22520.022Appendix 1---figure 1.Kinetic mechanisms.The four sequential kinetic mechanisms considered, along with the equations used to describe the fluorescence signal (the observable).**DOI:** [http://dx.doi.org/10.7554/eLife.22520.022](10.7554/eLife.22520.022)

Establishing the minimal kinetic scheme {#s46}
=======================================

We analyzed the fluorescence progress curves from the Cy3-AP3 promoter ([Figure 3A--C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}) using KinTek Global Kinetic Explorer software, which performs a global fit of a kinetic mechanism to an entire concentration series at once ([@bib32], [@bib33]). In our analysis, we imposed the condition that the same kinetic model applies to each sample (*Eco* holo, *Mbo* holo, *Mbo* holo+RbpA, *Mbo* holo+CarD, *Mbo* holo+RbpA+CarD). In other words, the different RNAPs (*Eco* or *Mbo*) or addition of factors altered the rate constants associated with the mechanism, but did not alter the basic mechanism. Based on previous analyses ([@bib8]; [@bib55]; [@bib59]; [@bib60]; [@bib65]), we considered only sequential (linear) kinetic schemes (1-step, 2-step, 3-step, 4-step; [Appendix 1---figure 1](#fig7){ref-type="fig"}).

For each sample, the software calculated rate constants, fluorescence scale factors (a, b, c, d, e; [Appendix 1---figure 1](#fig7){ref-type="fig"}), and χ^2^/DOF (DOF = degress of freedom), a 'goodness of fit' parameter. For a perfect fit to the data points, χ^2^/DOF = 1. Based on the fitted kinetic constants, we calculated the theoretical RPo t~1/2~ ([@bib75]) for comparison with the experimental values ([Figure 2C](#fig2){ref-type="fig"}):$$\frac{1}{k_{\text{d}}} = \ \frac{1}{k_{- 3}} + \ \frac{1 + \ \text{K}_{3}}{k_{- 2}} + \ \frac{\text{K}_{2} + \ \text{K}_{2}\text{K}_{3}}{k_{- 1}} + \ \frac{1}{k_{- 1}}$$

where t~1/2~ = ln(2)/*k*~d~.

For each sample dataset, the 1-step and 2-step models were rejected because: (1) the curves obviously did not fit the data ([Appendix 1---figure 2](#fig8){ref-type="fig"}); (2) the χ^2^/DOF was far from optimal ([Appendix 1---figure 2](#fig8){ref-type="fig"}; [Appendix 1---tables 1](#A-tbl1){ref-type="table"}--[5](#A-tbl5){ref-type="table"}); and (3) in many cases (1-step model: *Mbo* holo+CarD, *Mbo* holo+RbpA+CarD, *Eco* holo; 2-step model: *Mbo* holo+RbpA, *Mbo* holo+CarD, *Mbo* holo+RbpA+CarD), the calculated t~1/2~ of the promoter complexes was inconsistent with the experimental values ([Appendix 1---tables 1](#A-tbl1){ref-type="table"}--[5](#A-tbl5){ref-type="table"}). The 4-step model was also rejected, primarly because in every case, one of the fluorescence scale factors ('d', corresponding to the extra intermediate, RP3, introduced in the 4-step pathway) refined to a value near zero ([Appendix 1---tables 1](#A-tbl1){ref-type="table"}--[5](#A-tbl5){ref-type="table"}), indicating that adding this intermediate did not contribute to the fitting of the data and often rendered the kinetic constants associated with this intermediate (*k*~3~, *k*~-3~, *k*~4~, *k*~-4~) ill determined.10.7554/eLife.22520.023Appendix 1---figure 2.Fits of kinetic mechanisms to selected data.Plots showing the fluorescence signal vs. time after mixing *Eco* holo (left column), *Mbo* holo (middle column), or *Mbo* holo+RbpA (right column) with 1 nM Cy3-AP3 promoter ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) in a stopped flow fluorimeter. The experimental data are shown as points. The data were fit using the 1-step (top row), 2-step (middle row), or 3-step (bottom row) sequential kinetic scheme ([Appendix --figure 1](#fig7){ref-type="fig"}). The curve fits are shown as solid lines. The blue numbers show the χ^2^/DOF for each fit.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.023](10.7554/eLife.22520.023)10.7554/eLife.22520.024Appendix 1---table 1.Kinetic model determination for *Mbo* holo on the Cy3-AP3 promoter.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.024](10.7554/eLife.22520.024)*Mbo* holo^\*\*^Model\*1-step2-step3-step4-step*k*~1~ (M^−1^s^−1^)(1.1 ± 0.4) x 10^6^(7.8 ± 1.2) x 10^6^(9.5 ± 1.3) x 10^6^(9.9 ± 1.7) x 10^6^*k*~-1~ (s^−1^)(6.0 ± 2.2) x 10^−3^2.0 ± 0.22.0 ± 0.21.6 ± 0.3K~1~ (M^−1^)(1.8 ± 0.9) x 10^8^(3.9 ± 0.7) x 10^6^(4.8 ± 0.8) x 10^6^(6.2 ± 1.6) x 10^6^*k*~2~ (s^−1^)0.37 ± 0.020.40 ± 0.020.3 ± 0.07*k*~-2~ (s^−1^)(9.5 ± 2.3) x 10^−3^0.058 ± 0.0070.097 ± 0.021K~2~39 ± 106.9 ± 0.93.1 ± 1.0*k*~3~ (s^−1^)0.057 ± 0.0110.21 ± 0.16*k*~-3~ (s^−1^)0.015 ± 0.0042.2 ± 11.5K~3~3.8 ± 1.30.095 ± 0.504*k*~4~ (s^−1^)3.8 ± 25.5*k*~-4~ (s^−1^)0.048 ± 0.105K~4~0.025 ± 0.215χ^2^/DOF1.627441.156681.066221.06737*k*~d~^†^6.0 × 10^−3^9.4 × 10^−3^6.6 × 10^−3^6.0 × 10^−3^t~1/2~ (min)1.91.21.71.9t~1/2~^exp^ (min)^‡^\~2a0.480.550.300.65b1.30.810.510.83c1.41.21.8d1.20.026e1.5bkg1.30.160.410.064[^15][^16][^17][^18][^19][^20]10.7554/eLife.22520.025Appendix 1---table 2.Kinetic model determination for *Mbo* holo+RbpA on the Cy3-AP3 promoter.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.025](10.7554/eLife.22520.025)*Mbo* holo+RbpA^\*\*^Model\*1-step2-step3-step4-step*k*~1~ (M^−1^s^−1^)(6.4 ± 0.3) x 10^6^(1.2 ± 0.1) x 10^7^(1.5 ± 0.1) x 10^7^(1.6 ± 0.1) x 10^7^*k*~-1~ (s^−1^)(6.5 ± 1.1) x 10^−3^0.80 ± 0.071.1 ± 0.10.88 ± 0.09K~1~ (M^−1^)(9.9 ± 1.7) x 10^8^(1.5 ± 0.2) x 10^7^(1.4 ± 0.2) x 10^7^(1.8 ± 0.2) x 10^7^*k*~2~ (s^−1^)1.1 ± 0.11.4 ± 0.10.81 ± 0.08*k*~-2~ (s^−1^)0.017 ± 0.0020.090 ± 0.0200.062 ± 0.030K~2~65 ± 1016 ± 413 ± 6*k*~3~ (s^−1^)0.046 ± 0.0150.59 ± 0.75*k*~-3~ (s^−1^)0.011 ± 0.0041.6 ± 0.7K~3~4.2 ± 2.00.37 ± 0.50*k*~4~ (s^−1^)0.091 ± 0.193*k*~-4~ (s^−1^)(9.9 ± 14) x 10^−3^K~4~4.1 ± 10.2χ^2^/DOF1.477861.242411.112681.10116*k*~d~^†^6.4 × 10^−3^0.0166.4 × 10^−3^3.6 × 10^−3^t~1/2~ (min)1.80.711.83.2t~1/2~^exp^ (min)^‡^\~1.5a0.0990.0380.160.65b1.20.700.680.83c1.11.31.8d1.30.026e1.5bkg0.810.860.740.064[^21][^22][^23][^24][^25][^26]10.7554/eLife.22520.026Appendix 1---table 3.Kinetic model determination for *Mbo* holo+CarD on the Cy3-AP3 promoter.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.026](10.7554/eLife.22520.026)*Mbo* holo+CarD\*\*Model\*1-step2-step3-step4-step*k*~1~ (M^−1^s^−1^)(1.3 ± 0.1) x 10^7^(5.4 ± 0.4) x 10^7^(5.8 ± 0.5) x 10^7^(3.8 ± 0.3) x 10^7^*k*~-1~ (s^−1^)(3.2 ± 1.4) x 10^−3^10 ± 16.2 ± 1.01.4 ± 0.2K~1~ (M^−1^)(4.1 ± 1.8) x 10^9^(5.4 ± 0.7) x 10^6^(9.4 ± 1.7) x 10^6^(2.7 ± 0.4) x 10^7^*k*~2~ (s^−1^)4.0 ± 0.33.1 ± 0.21.1 ± 0.2*k*~-2~ (s^−1^)(2.7 ± 1.8) x 10^−3^0.067 ± 0.0190.049 ± 0.024K~2~1500 ± 9946 ± 1422 ± 12*k*~3~ (s^−1^)0.074 ± 0.0270.72 ± 0.41*k*~-3~ (s^−1^)(2.5 ± 3.0) x 10^−3^1.4 ± 0.4K~3~30 ± 370.51 ± 0.32*k*~4~ (s^−1^)0.11 ± 0.06*k*~-4~ (s^−1^)(3.9 ± 5.3) x 10^−3^K~4~4.7 ± 3.9χ^2^/DOF1.349031.224481.108771.1021*k*~d~^†^3.2 × 10^−3^2.6 × 10^−3^1.1 × 10^−3^1.2 × 10^−3^t~1/2~ (min)3.64.3109.6t~1/2~^exp^ (min)^‡^\~10a0.500.560.280.80b1.50.750.451.1c1.51.22.6d1.25.3 × 10^−5^e1.8bkg0.310.240.522.9 × 10^−3^[^27][^28][^29][^30][^31][^32]10.7554/eLife.22520.027Appendix 1---table 4.Kinetic model determination for *Mbo* holo+RbpA+CarD on the Cy3-AP3 promoter.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.027](10.7554/eLife.22520.027)*Mbo* holo+RbpA+CarD^\*\*^Model\*1-step2-step3-step4-step*k*~1~ (M^−1^s^−1^)(2.7 ± 0.1) x 10^7^(1.2 ± 0.2) x 10^8^(1.1 ± 0.2) x 10^8^(5.4 ± 0.3) x 10^7^*k*~-1~ (s^−1^)(6.1 ± 1.5) x 10^−3^27 ± 520 ± 52.0 ± 0.4K~1~ (M^−1^)(4.4 ± 1.1) x 10^9^(4.4 ± 1.1) x 10^6^(5.5 ± 1.7) x 10^6^(2.7 ± 0.6) x 10^7^*k*~2~ (s^−1^)9.6 ± 0.49.7 ± 0.53.9 ± 0.5*k*~-2~ (s^−1^)1.1 × 10^−7^0.031 ± 0.0110.11 ± 0.43K~2~8.7 × 10^7^310 ± 1135 ± 140*k*~3~ (s^−1^)0.13 ± 0.0311 ± 34*k*~-3~ (s^−1^)(1.3 ± 8.2) x 10^−3^9.0 ± 30K~3~100 ± 631.2 ± 5.6*k*~4~ (s^−1^)0.16 ± 0.42*k*~-4~ (s^−1^)(2.9 ± 3800) x 10^6^K~4~7.6 ± 40χ^2^/DOF1.323671.094731.050351.0458*k*~d~^†^6.1 × 10^−3^1.1 × 10^−7^2.5 × 10^−4^4.3 × 10^−7^t~1/2~ (min)1.91.1 × 10^5^472.7 × 10^4^t~1/2~^exp^ (min)^‡^\~30a0.590.630.280.91b1.70.630.280.95c1.61.24.2d1.35.7 × 10^−6^e1.9bkg0.340.280.631.1 × 10^−6^[^33][^34][^35][^36][^37][^38]10.7554/eLife.22520.028Appendix 1---table 5.Kinetic model determination for *Eco* holo on the Cy3-AP3 promoter.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.028](10.7554/eLife.22520.028)*Eco* holo^\*\*^Model\*1-step2-step3-step4-step*k*~1~ (M^−1^s^−1^)(9.9 ± 0.7) x 10^6^(1.2 ± 0.1) x 10^8^(1.2 ± 0.1) x 10^8^(8.5 ± 0.6) x 10^7^*k*~-1~ (s^−1^)(2.7 ± 2.2) x 10^−3^4.6 ± 0.73.4 ± 0.51.1 ± 0.1K~1~ (M^−1^)(3.7 ± 3.0) x 10^9^(2.6 ± 0.5) x 10^7^(3.5 ± 0.6) x 10^7^(7.7 ± 0.9) x 10^7^*k*~2~ (s^−1^)1.0 ± 0.011.2 ± 0.030.39 ± 0.04*k*~-2~ (s^−1^)\~ 00.11 ± 0.010.024 ± 0.023K~2~-11 ± 116 ± 16*k*~3~ (s^−1^)0.083 ± 0.0150.66 ± 0.25*k*~-3~ (s^−1^)\~ 00.65 ± 0.19K~3~-1.0 ± 0.5*k*~4~ (s^−1^)0.048 ± 0.119*k*~-4~ (s^−1^)\~ 0K~4~-χ^2^/DOF4.079411.452731.06311.04588*k*~d~^†^2.7 × 10^−3^\~ 0\~ 0\~ 0t~1/2~ (min)4.3\-\--t~1/2~^exp^ (min)^‡^\>\>60a0.530.550.520.60b1.50.810.620.72c1.41.42.9d1.46.1 × 10^−4^e1.5bkg0.320.160.280.20[^39][^40][^41][^42][^43][^44]

The 3-step sequential model applied to each data set well: it visually fit the data ([Figure 3A--C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}), it gave χ^2^/DOF values close to 1 ([Appendix 1---figure 2](#fig8){ref-type="fig"}; [Appendix 1---tables 1](#A-tbl1){ref-type="table"}--[5](#A-tbl5){ref-type="table"}), and for every sample, the calculated t~1/2~ matched well with the experimental values ([Appendix 1---tables 1](#A-tbl1){ref-type="table"}--[5](#A-tbl5){ref-type="table"}). Thus, for each sample, a concentration series was collected on a given day and fitted to the 3-step model. Concentration series collected on separate days were fitted separately, yielding similar constants. The constants derived in this way were then averaged, giving rise to the average values and standard errors listed in [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}.

**Validation of kinetic parameter estimation** (see [@bib32] for a more detailed discussion)

Like other programs for fitting data by nonlinear regression, KinTek Global Kinetic Explorer provides a covariance matrix from which standard errors are calculated to give estimates of the confidence intervals on fitted parameters ([@bib32]). However, standard errors computed in this way underestimate the true error, and may not be valid at all. The fitting process assumes that all experimental errors are uncorrelated and normally distributed, which is not necessarily the case for complex kinetic models, where sets of parameters can be correlated in ways that are not obvious. Moreover, the covariance matrix is not valid when the parameters are underconstrained by the data. The practical manifestation of this is that the set of parameter values determined to be the best fit (i.e. a minimum in the sum square error, or SSE, with the experimental data) may not be unique; sets of parameters that are correlated may vary systematically over a wide range and give rise to an equally good fit to the data given appropriate adjustments of the remaining parameters. For this reason, it is difficult to evaluate whether the set of parameters are adequately constrained by the data.

In contour confidence analysis ('FitSpace' calculations in the KinTek Global Kinetic Explorer software; ([@bib32]), a given pair of parameters (x, y; the test parameters) are varied systematically around the area of their best fit. At each pair of x, y values of the test parameters, the experimental data are fit by allowing all of the other parameters to vary while holding the test parameters fixed. After convergence to the best fit, the sum of squared errors (SSE) is computed. In this way, a profile of the SSE over the grid of tested x, y values is constructed. This process is then repeated for all possible pairs of parameters. This defines the extent to which pairs of parameters are correlated and individual parameters are constrained by the data without making assumptions regarding the values of the other parameters.

The FitSpace calculations for some of the fits to individual concentration series datasets (used to derive the values listed in [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}) revealed that some of the parameters for some of the fits were not well constrained. We imposed additional constraints on the data to reduce the degress of freedom for the fitted parameters:

1.  First, we combined the independent trials for each sample and analyzed them together rather than separately (all samples).

2.  Second, for samples where dissociation data were available (*Mbo* holo and *Mbo* holo+RbpA; [Figure 3---figure supplement 1D--E](#fig3s1){ref-type="fig"}), we included those data in the combined analysis.

3.  Third, for *Mbo* holo, we included the results of the 2-AP experiment ([Figure 3D](#fig3){ref-type="fig"}) in the combined analysis.

4.  Fourth, for *Eco* holo, the unconstrained parameter was *k*~-3~, which was very small in magnitude relative to the other rate constants and could vary over several orders of magnitude without affecting the fit. In this case, we fixed the value of *k*~-3~ to zero.

5.  Finally, for the other samples where dissociation data were not available (*Mbo* holo+CarD, *Mbo* holo+RbpA+CarD), we used an iterative procedure to require that the fitted kinetic parameters yielded the observed experimental t~1/2~ for each sample and fixed *k*~-3~, as detailed here:We determined that the calculated RPo t~1/2~ (using [Equations 2 and 3](#equ9){ref-type="disp-formula"}, main manuscript) was most sensitive to the value of *k*~-3~ (compared to all the other parameters). Therefore, for each dataset (*Mbo* holo+CarD, *Mbo* holo+RbpA+CarD), we adjusted the value of *k*~-3~ until the calculated RPo t~1/2~ was equal to the experimentally determined value (to within roundoff error). We then fixed *k*~-3~ and refined the other constants against the fluorescence data. We iteratively adjusted *k*~-3~ and refined the other values so that the final calculated RPo t~1/2~ was equal to the experimentally determined value, and the refinement of the other constants stabilized (i.e. the values didn't change during refinement). Note that since the initial (unrestrained) refinements resulted in calculated RPo t~1/2~ values that were already close to the experimental values ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}), this procedure did not require dramatic changes to the constants but resulted in a final refinement in which *k*~-3~ was fixed.

The final refinement and FitSpace calculations for each sample are described below:

*Eco* holo {#s47}
----------

For *Eco* holo, we only collected one concentration series ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"}; [Figure 3A](#fig3){ref-type="fig"}). FitSpace calculations on the unconstrained fit revealed that the parameter *k*~-3~ was poorly constrained by the data; the value of *k*~-3~ could vary from zero over several orders of magnitude with little effect on the fit of the remaining parameters. The experimental determination of the RPo t~1/2~ for *Eco* holo on AP3 could only provide a lower bound, since over the time course of up to 2 hr experiments, essentially no dissociation was observed ([@bib16]). We listed the t~1/2~ as \>\>60 min ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}). We therefore fixed *k*~-3~ to zero. The χ^2^/DOF value was unaltered (1.063 whether *k*~-3~ was fixed at zero or not; [Appendix 1---figure 2](#fig8){ref-type="fig"}). The resulting FitSpace calculation showed that the remaining parameters (*k*~1~, *k*~-1~, *k*~2~, *k*~-2~, *k*~3~) were constrained ([Appendix 1---figure 3](#fig9){ref-type="fig"}).10.7554/eLife.22520.029Appendix 1---figure 3.FitSpace calculation for *Eco* holo (*k*~-3~ = 0).The results of the contour confidence analysis for *Eco* holo (parameters listed in [Table 1](#tbl1){ref-type="table"}) with *k*~-3~ fixed at 0. Each panel represents a grid where two kinetic parameters were varied systematically. For example, the upper left panel shows the result of systematically varying *k*~1~ from 3.74 × 10^7^ to 8.51 × 10^8^ M^−1^s^−1^ (x-axis) and *k*~-1~ from 0.393 to 110 s^−1^ (y-axis). At each point, the values of *k*~1~ and *k*~-1~ were fixed, then the other parameters (*k*~2~, *k*~-2~, *k~3~*) were refined against the data (the fluorescence progress curves; [Figure 3A](#fig3){ref-type="fig"}). The resulting sum squared error (SSE) is normalized by the minimum SSE (SSE~min~) and plotted as a heat map. The minimum SSE (normalized by itself, so with a value of 1) is red in the heat map, higher SSE values are color-coded as shown. Each panel shows that the optimal pair of parameter values are restricted to a small red area, indicating the parmeters are constrained by the data.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.029](10.7554/eLife.22520.029)

*Mbo* holo {#s48}
----------

The datasets combined and analyzed globally included three independent association concentration series (such as shown in [Figure 3B](#fig3){ref-type="fig"}, [Appendix 1---figure 2](#fig8){ref-type="fig"}), one dissociation experiment ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), and the 2-AP experiment ([Figure 3D](#fig3){ref-type="fig"}). The global refinement weight for each of the association datasets was set to 1, while the weight for the dissociation and 2-AP experiment was set to 2. The FitSpace calculation showed that the fitted kinetic parameters were constrained ([Appendix 1---figure 4](#fig10){ref-type="fig"}).10.7554/eLife.22520.030Appendix 1---figure 4.FitSpace calculation for *Mbo* holo.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.030](10.7554/eLife.22520.030)

*Mbo* holo+RbpA {#s49}
---------------

The datasets combined and analyzed globally included two independent association concentration series (such as shown in [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}, [Appendix 1---figure 2](#fig8){ref-type="fig"}) and one dissociation experiment ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). The global refinement weight for each of the association datasets was set to 1, while the weight for the dissociation experiment was set to 2. The FitSpace calculation showed that the fitted kinetic parameters were constrained ([Appendix 1---figure 5](#fig11){ref-type="fig"}).10.7554/eLife.22520.031Appendix 1---figure 5.FitSpace calculation for *Mbo* holo+RbpA.**DOI:** [http://dx.doi.org/10.7554/eLife.22520.031](10.7554/eLife.22520.031)

*Mbo* holo+CarD {#s50}
---------------

The datasets combined and analyzed globally included two independent association concentration series (such as shown in [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). An iterative procedure was followed wherein *k*~-3~ was adjusted so that the calculated RPo t~1/2~ matched the experimental value of 10 min ([Figure 2C](#fig2){ref-type="fig"}). The value of *k*~-3~ was then fixed, and the remaining parameters were refined. This procedure was repeated until the refinement stabilized on a set of values yielding a calculated RPo t~1/2~ as close to 10 min as possible. This led to the fixed value of *k*~-3~=2.3×10^−3^ s^−1^. The FitSpace calculation showed that the remaining kinetic parameters were constrained ([Appendix 1---figure 6](#fig12){ref-type="fig"}).10.7554/eLife.22520.032Appendix 1---figure 6.FitSpace calculation for *Mbo* holo+CarD (*k*~-3~ = 2.3×10^−3^ s^−1^).**DOI:** [http://dx.doi.org/10.7554/eLife.22520.032](10.7554/eLife.22520.032)

*Mbo* holo+RbpA+CarD {#s51}
--------------------

The datasets combined and analyzed globally included two independent association concentration series (such as shown in [Figure 3C](#fig3){ref-type="fig"}). An iterative procedure was followed wherein *k*~-3~ was adjusted so that the calculated RPo t~1/2~ matched the experimental value of 30 min ([Figure 2C](#fig2){ref-type="fig"}). The value of *k*~-3~ was then fixed, and the remaining parameters were refined. This procedure was repeated until the refinement stabilized on a set of values yielding a calculated RPo t~1/2~ as close to 30 min as possible. This led to the fixed value of *k*~-3~=1.3×10^−3^ s^−1^. The FitSpace calculation showed that the remaining fitted kinetic parameters were constrained with the exception of *k*~1~ ([Appendix 1---figure 7](#fig13){ref-type="fig"}).10.7554/eLife.22520.033Appendix 1---figure 7.FitSpace calculation for *Mbo* holo+RbpA+CarD (*k*~-3~ = 1.3×10^−3^ s^−1^).**DOI:** [http://dx.doi.org/10.7554/eLife.22520.033](10.7554/eLife.22520.033)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Structure and function of the mycobacterial transcription initiation complex with the essential regulator RbpA\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, including Ann Hochschild (Reviewer \#2), and the evaluation has been overseen by a Reviewing Editor and Richard Losick as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is a thorough, definitive paper that addresses a number of questions about Mycobacterial promoters and their regulation by the transcription factors RbpA and CarD. It reports a high resolution crystal structure (2.76Å) of RpbA in complex with mycobacterial RNA polymerase, a detailed kinetic analysis deriving from extensive experiments using a fluorescence assay that reports on open complex formation, structure-function analysis of RbpA and RpbA mutants on transcription, a model for how RpbA and CarD work together, RNA-seq gene expression analysis addressing the impact of RpbA and its domains genome-wide, and microscopic analysis of cell morphology expressing the various RpbA mutants. The results explain how two transcription factors, RpbA and CarD, both can act on the transcription complex simultaneously and can synergize. The findings are for the most part clear and compelling, though the in vivo results with the RbpA R79A mutant are somewhat puzzling and may warrant further discussion (see below). The manuscript might also benefit from some tightening/shortening.

Essential revisions:

1\) Subsection "Full-length RbpA is essential for normal growth of *Msm*": The viability of the RbpA-R79A mutant is somewhat surprising, especially given the repressive effects of this mutant as seen in vitro ([Figure 2B](#fig2){ref-type="fig"}). Do the authors believe that the in vitro assays are more sensitive and that, in vivo, the BL can still engage the DNA phosphate backbone even in the absence of the R79 side chain? Some discussion of this apparent discrepancy would be helpful (see also comment 4, below).

2\) Subsection "Full-length RbpA is essential for normal growth of *Msm*" and [Figure 5A](#fig5){ref-type="fig"}: The cell morphology images are difficult to interpret; the differences the authors highlight in the text are hard to appreciate visually. For just one example, the Hoechst stain in the upper panel of the RbpA^CD-BL-SID^ sample reveals two foci that look very similar to the apparently aberrant structures in the top panel of the RbpA^BL-SID^ sample (designated condensed nucleoid). This panel should be improved or eliminated.

3\) Subsection "Differential effects of RbpA domains on gene expression in vivo": How do the authors interpret this observation -- that the loss of the NTT results in changes in gene expression that are not seen when both the NTT and the CD are removed? It is as if removal of the CD suppresses the effects of removing the NTT.

4\) Subsection "RP2", end of third paragraph: The suggestion that the interaction of RbpA residue R79 with the nt strand -13 phosphate fulfills an essential anchoring role, while mechanistically satisfying, must still be reconciled with the viability of the RbpA-R79A allele, especially given that most *Mtb* promoters lack a -35 element.

5\) Abstract. \"Unlike *E. coli* RPo, Mycobacterial RPo is highly reversible.\" Later in the paper the authors go on to show that the two RNAPs differ in the stability of the complexes they form even on the same promoter, but at this point the blanket statement is misleading. *E. coli* also forms highly reversible complexes on certain promoters.

6\) Subsection "The RbpA-R79/DNA interaction is critical for RbpA in vitro function", first paragraph, and first sentence in Discussion. Earlier ChIP-seq studies indicated that CarD is present on most/all σ A-dependent promoters, and the work presented here shows that RbpA works in conjunction with RbpA on some promoters. However, the sentence implies that RbpA also functions genome-wide. Is that what the authors mean to say? If not, please rephrase, and if so, please describe the data that justify this statement.

7\) Subsection "The RbpA-R79/DNA interaction is critical for RbpA in vitro function", third paragraph. [Figure 2B](#fig2){ref-type="fig"}. I found this figure difficult to understand, and specifically I could not figure out where the statement \"decreased more than 10-fold\" came from. What is the Y-axis?

8\) Subsection "RbpA and CarD Affect Distinct Kinetic Steps of RPo Formation on AP3", last sentence in first paragraph. Although it is true that there is a real advantage of studying kinetics without competitors like heparin, and they have included the word \"mostly\", there have been many studies of association kinetics without competitors. Maybe it would be better to just clearly state why it is best to study kinetics without perturbants, without implying that such studies are rare.

9\) The kinetics section in the Results seems a bit long-winded. Can it be condensed for readability? At the same time, it would be helpful for the casual reader to state that the energy profile (i.e. [Figure 3F](#fig3){ref-type="fig"}) is simply a replot using the kinetic constants derived in parts A-E, using software described in the Johnson et al. papers. The extensive \"Appendix\" is overwhelming. [Supplementary file 4](#SD4-data){ref-type="supplementary-material"} does not fit on the page in the PDF.

10\) Subsection "RP1", second paragraph: discrepancy with Rammohan et al. 2015. Are there other explanations for the discrepancy besides \"buffer composition\"? I understand that glutamate buffers would tend to stabilize complexes and alter the overall rates across the board, but would this really change the conclusions about the basic mechanism?

11\) Subsection "RbpA function in vivo" and last line in [Figure 5](#fig5){ref-type="fig"} legend (\"See supplemental dataset for gene lists corresponding to each color class\"). I assume the authors are referring to the Excel files provided. It is nice that the authors are providing these data for the community. Given the massive amounts of data in this paper, I\'m not asking for more, but there must be something interesting about specific transcripts that would be useful to point out.

10.7554/eLife.22520.047

Author response

*Essential revisions:*

*1) Subsection "Full-length RbpA is essential for normal growth of Msm": The viability of the RbpA-R79A mutant is somewhat surprising, especially given the repressive effects of this mutant as seen in vitro ([Figure 2B](#fig2){ref-type="fig"}). Do the authors believe that the in vitro assays are more sensitive and that, in vivo, the BL can still engage the DNA phosphate backbone even in the absence of the R79 side chain? Some discussion of this apparent discrepancy would be helpful (see also comment 4, below).*

We have added the following to the Discussion section:

"In our in vitroanalyses, RbpA^R79A^ by itself appeared to have lost all RbpA function in activating transcription and counteracted the activity of CarD when both factors were present ([Figure 2B](#fig2){ref-type="fig"}, [Supplementary file 7](#SD7-data){ref-type="supplementary-material"}). \[...\] It seems likely that other promoters are regulated by RbpA^R79A^ in vivo, possibly through the action of additional conserved basic residues on the BL such as K76 ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"})."

*2) Subsection "Full-length RbpA is essential for normal growth of Msm" and [Figure 5A](#fig5){ref-type="fig"}: The cell morphology images are difficult to interpret; the differences the authors highlight in the text are hard to appreciate visually. For just one example, the Hoechst stain in the upper panel of the RbpA^CD-BL-SID^ sample reveals two foci that look very similar to the apparently aberrant structures in the top panel of the RbpA^BL-SID^ sample (designated condensed nucleoid). This panel should be improved or eliminated.*

We have quantitated the nuclear morphology:

"We scored nucleoid morphology as either condensed or diffuse in WT (n=208) and RbpA^BL-SID^ (n=248) and observed that condensed nucleoids were present in 2.4% of WT cells, whereas 25% of RbpA^BL-SID^ nucleoids were condensed ([Figure 5A](#fig5){ref-type="fig"})."

We have also included a histogram of the results in a revised [Figure 5](#fig5){ref-type="fig"} and have modified the [Figure 5](#fig5){ref-type="fig"} legend accordingly.

*3) Subsection "Differential effects of RbpA domains on gene expression in vivo": How do the authors interpret this observation -- that the loss of the NTT results in changes in gene expression that are not seen when both the NTT and the CD are removed? It is as if removal of the CD suppresses the effects of removing the NTT.*

We think this is a misunderstanding due to some confusing wording. We have clarified:

Previously: "First, despite the complete complementation by RbpA^CD-BL-SID^ for viability, growth, and cell morphology, loss of the NTT had clear effects on gene expression that were [not found in]{.ul} RbpA^BL-SID^, including both overexpressed and underexpressed genes (see red and blue dots, [Figure 5C](#fig5){ref-type="fig"})."

Revised: "First, despite the complete complementation by RbpA^CD-BL-SID^ for viability, growth, and cell morphology, loss of the NTT had clear effects on gene expression that were [distinct from]{.ul} RbpA^BL-SID^, including both overexpressed and underexpressed genes (see red and blue dots, [Figure 5C](#fig5){ref-type="fig"})."

*4) Subsection "RP2", end of third paragraph: The suggestion that the interaction of RbpA residue R79 with the nt strand -13 phosphate fulfills an essential anchoring role, while mechanistically satisfying, must still be reconciled with the viability of the RbpA-R79A allele, especially given that most Mtb promoters lack a -35 element.*

See response to point 1.

*5) Abstract. \"Unlike E. coli RPo, Mycobacterial RPo is highly reversible.\" Later in the paper the authors go on to show that the two RNAPs differ in the stability of the complexes they form even on the same promoter, but at this point the blanket statement is misleading. E. coli also forms highly reversible complexes on certain promoters.*

We have rewritten the Abstract and this statement is removed.

*6) Subsection "The RbpA-R79/DNA interaction is critical for RbpA* in vitro *function", first paragraph, and first sentence in Discussion. Earlier ChIP-seq studies indicated that CarD is present on most/all σ A-dependent promoters, and the work presented here shows that RbpA works in conjunction with RbpA on some promoters. However, the sentence implies that RbpA also functions genome-wide. Is that what the authors mean to say? If not, please rephrase, and if so, please describe the data that justify this statement.*

We have added a paragraph to the Introduction explaining why we think CarD and RbpA function together:

"ChIP-seq studies indicate CarD is present at most, if not all s^A^ promoters in mycobacteria (Srivastava et al., 2013). \[...\] Thus, the structural mechanism for CarD and RbpA function must be compatible with the two transcription activators acting simultaneously on the mycobacterial TIC."

*7) Subsection "The RbpA-R79/DNA interaction is critical for RbpA in vitro function", third paragraph. [Figure 2B](#fig2){ref-type="fig"}. I found this figure difficult to understand, and specifically I could not figure out where the statement \"decreased more than 10-fold\" came from. What is the Y-axis?*

The y-axis title for [Figure 2B](#fig2){ref-type="fig"}, which was inadvertantly left out, has been added, and additional explanation of the normalization procedure has been added to the Figure legend. The transcription activity for each promoter was normalized with respect to holo activity on that promoter (this is because transcription on the AP3anti-35 promoter was so weak compared to the other promoters, the plot of absolute values is difficult to see what is going on with AP3anti-35. Because of the normalization procedure, this figure does not illustrate the transcription activity of each promoter compared to the other promoters. The abortive transcription gels in [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"} also do not illustrate this because the assays for the different promoters were conducted with different specific activities of radioactivity. We have added [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}, which shows transcription on AP3 and AP3anti-35 under conditions where they can be directly compared -- this figure shows how holo on AP3anti-35 is \~10-fold weaker than holo on AP3.

*8) Subsection "RbpA and CarD Affect Distinct Kinetic Steps of RPo Formation on AP3", last sentence in first paragraph. Although it is true that there is a real advantage of studying kinetics without competitors like heparin, and they have included the word \"mostly\", there have been many studies of association kinetics without competitors. Maybe it would be better to just clearly state why it is best to study kinetics without perturbants, without implying that such studies are rare.*

This is a misunderstanding -- the word 'perturbative' here was meant to refer to non-real time approaches for measuring RPo formation kinetics (where the reaction had to be perturbed in order to measure something). We have simply deleted the word 'perturbative' (to avoid confusion), so the sentence now reads:

"This pathway (Equation 1) has been studied using mostly approaches that require the RPo reactions to be halted, then probed \[...\]"

*9) The kinetics section in the Results seems a bit long-winded. Can it be condensed for readability? At the same time, it would be helpful for the casual reader to state that the energy profile (i.e. [Figure 3F](#fig3){ref-type="fig"}) is simply a replot using the kinetic constants derived in parts A-E, using software described in the Johnson et al. papers. The extensive \"Appendix\" is overwhelming. [Supplementary file 4](#SD4-data){ref-type="supplementary-material"} does not fit on the page in the PDF.*

We have edited the kinetics section to make it easier to digest by: 1) shortening it a bit, and 2) reorganizing it and breaking it up with section headings.

Appendix -- It is important to point out that this type of analysis, where all of the forward and reverse rate constants for the entire kinetic mechanism of RPo formation have been determined, is done here for the first time. It is critical that others understand exactly what was done here. Moreover, in this type of fitting exercise the potential for 'overfitting', i.e. assigning values to parameters that are not constrained or not unique, is high. It is essential that the methods and the results be rigorously validated. Therefore, it is essential that the material presented in the Appendix be included with the manuscript. We realize not everyone will be interested in the material presented in the Appendix and may be overwhelmed, but that is precisely why it is included as an Appendix. Papers such as this that present complex analyses often contain Appendices to explain the details of the analyses, and when they do not it is often very difficult or impossible to understand how the analysis was actually done.

[Supplementary file 4](#SD4-data){ref-type="supplementary-material"} has been reformatted and the main table fits on one page.

*10) Subsection "RP1", second paragraph: discrepancy with Rammohan et al. 2015. Are there other explanations for the discrepancy besides \"buffer composition\"? I understand that glutamate buffers would tend to stabilize complexes and alter the overall rates across the board, but would this really change the conclusions about the basic mechanism?*

The reviewer points out a valid concern: overall we do not know enough about the steps and the detailed conformational changes involved to make a convincing case that buffer composition resulted in a difference between our results and theirs. Detailed examination of the previously published work (Rahhoman et al. 2015) reveals that the authors\' proposal that CarD destabilizes RPc (relative to RPc without CarD) is not supported by their analysis. Comparing these relative stabilities requires the binding constant for forming RPc from R\*CarD + P: this equilibrium was not part of their model. We believe the conclusion about the destabilization of RPc by CarD arose from the interpretation of their data in the framework of a two-step kinetic model:

R + P = RPc = RPo

while we showed rigorously here that a three-step kinetic scheme is necessary to account for the data (Appendix).

We have added a paragraph (--subsection "RP1", last paragraph) to outline how our approach differs from the previously published one and its key advantages in regards to the following: analyzing the data without having to interpret multi- exponentials, working at saturating concentrations of the regulators, interpreting the results in the context of the 3-step kinetic model (shown here to apply) instead of the 2-step model, and comparing resulting parameters of the fit (kd calculated from microscopic rates) to independently, experimentally determined values of kd.

*11) Subsection "RbpA function in vivo" and last line in [Figure 5](#fig5){ref-type="fig"} legend (\"See supplemental dataset for gene lists corresponding to each color class\"). I assume the authors are referring to the Excel files provided. It is nice that the authors are providing these data for the community. Given the massive amounts of data in this paper, I\'m not asking for more, but there must be something interesting about specific transcripts that would be useful to point out.*

We attempted to segregate the different classes of RbpA-regulated transcripts into functional classes, but no meaningful patterns emerged. Further analysis along these lines is ongoing.

[^1]: Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.

[^2]: Color coding:.

[^3]: Grey: 5--10-fold \> *Mbo* holo; Pink: 5--10-fold \< *Mbo* holo.

[^4]: Green: \> 10 fold over *Mbo* holo; Red: more than 10-fold \< *Mbo *holo.

[^5]: Bold text denotes that that parameter was fixed during the refinement (see Appendix).

[^6]: \*\*\*Because the independent trials for each sample were analyzed together, we could not calculate errors in the fitted parameters across trials. The standard errors from the fits are likely to be underestimates of the errors (Johnson et al., 2009a; 2009b). Therefore, Table 1 does not report errors in the fitted parameters and we presume the errors are around 10--15%, as seen in the unconstrained analysis (Supplementary file 4).

[^7]: \*Number of independent trials.

[^8]: ^†^Includes three association series ([Figure 3B](#fig3){ref-type="fig"}), one dissociation experiment ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), and the 2-AP experiment ([Figure 3E](#fig3){ref-type="fig"}).

[^9]: ^‡^Includes three association series ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}) and one dissociation experiment ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}).

[^10]: ^§^The values for K~1~, K~2~, and K~3~ were calculated from the fitted parameters: K~1~ = *k*~1~/*k*~-1~, K~2~ = *k*~2~/*k*~-2~, K~3~=*k*~3~/*k*~-3~.

[^11]: ^¶^The value for *k*~d~, the dissociation rate for RPo, was calculated using equation (17) of [@bib75]:.

[^12]: $$\frac{1}{k_{\text{d}}} = \ \frac{1}{k_{- 3}} + \ \frac{1 + \ \text{K}_{3}}{k_{- 2}} + \ \frac{\text{K}_{2} + \ \text{K}_{2}\text{K}_{3}}{k_{- 1}} + \ \frac{1}{k_{- 1}}$$.

[^13]: The value for t~1/2~ was calculated as t~1/2~ = ln(2)/*k*~d~.

[^14]: \*\*The experimental half-life (t~1/2~^exp^) was determined from promoter lifetime experiments ([Figure 2C](#fig2){ref-type="fig"}).

[^15]: \*[Appendix 1---figure 1](#fig7){ref-type="fig"}.

[^16]: \*\*The errors listed are the standard errors from the global fit as reported by Kintek Global Kinetic Explorer (Johnson et al., 2009a).

[^17]: ^†^For the 1-step, 2-step, and 3-step models, the value for *k*~d~, the dissociation rate for RPo, was calculated using equation (17) of ([@bib75]):.

[^18]: $$\frac{1}{k_{\text{d}}} = \ \frac{1}{k_{- 3}} + \ \frac{1 + \ \text{K}_{3}}{k_{- 2}} + \ \frac{\text{K}_{2} + \ \text{K}_{2}\text{K}_{3}}{k_{- 1}} + \ \frac{1}{k_{- 1}}$$.

[^19]: For the 1-step model, K~2~ = K~3~ = 0, *k*~-2~ = *k*~-3~ = ∞; for the 2-step model, K~3~ = 0, *k*~-3~ = ∞. For the 4-step model, dissociation was simulated and the result was fit to a single exponential decay to derive *k*~d~. The value for t~1/2~ was calculated as t~1/2~ = ln(2)/*k*~d~.

[^20]: ^‡^The experimental half-life (t~1/2~^exp^) was determined from promoter lifetime experiments ([Figure 2C](#fig2){ref-type="fig"}).

[^21]: \*[Appendix 1---figure 1](#fig7){ref-type="fig"}.

[^22]: ^\*\*^The errors listed are the standard errors from the global fit as reported by Kintek Global Kinetic Explorer (Johnson et al., 2009a).

[^23]: ^†^TT For the 1-step, 2-step, and 3-step models, the value for *k*~d~, the dissociation rate for RPo, was calculated using equation (17) of ([@bib75]):.

[^24]: $$\frac{1}{k_{\text{d}}} = \ \frac{1}{k_{- 3}} + \ \frac{1 + \ \text{K}_{3}}{k_{- 2}} + \ \frac{\text{K}_{2} + \ \text{K}_{2}\text{K}_{3}}{k_{- 1}} + \ \frac{1}{k_{- 1}}$$.

[^25]: For the 1-step model, K~2~ = K~3~ = 0, *k*~-2~ = *k*~-3~ = ∞; for the 2-step model, K~3~ = 0, *k*~-3~ = ∞. For the 4-step model, dissociation was simulated and the result was fit to a single exponential decay to derive *k*~d~. The value for t~1/2~ was calculated as t~1/2~ = ln(2)/*k*~d~.

[^26]: ^‡^The experimental half-life (t~1/2~^exp^) was determined from promoter lifetime experiments ([Figure 2C](#fig2){ref-type="fig"}).

[^27]: \*[Appendix 1---figure 1](#fig7){ref-type="fig"}.

[^28]: \*\*The errors listed are the standard errors from the global fit as reported by Kintek Global Kinetic Explorer (Johnson et al., 2009a).

[^29]: ^†^For the 1-step, 2-step, and 3-step models, the value for *k*~d~, the dissociation rate for RPo, was calculated using equation (17) of [@bib75]:.

[^30]: $$\frac{1}{k_{\text{d}}} = \ \frac{1}{k_{- 3}} + \ \frac{1 + \ \text{K}_{3}}{k_{- 2}} + \ \frac{\text{K}_{2} + \ \text{K}_{2}\text{K}_{3}}{k_{- 1}} + \ \frac{1}{k_{- 1}}$$.

[^31]: For the 1-step model, K~2~ = K~3~ = 0, *k*~-2~ = *k*~-3~ = ∞; for the 2-step model, K~3~ = 0, *k*~-3~ = ∞. For the 4-step model, dissociation was simulated and the result was fit to a single exponential decay to derive *k*~d~. The value for t~1/2~ was calculated as t~1/2~ = ln(2)/*k*~d~.

[^32]: ^‡^The experimental half-life (t~1/2~^exp^) was determined from promoter lifetime experiments ([Figure 2C](#fig2){ref-type="fig"}).

[^33]: \*[Appendix 1---figure 1](#fig7){ref-type="fig"}.

[^34]: \*\*The errors listed are the standard errors from the global fit as reported by Kintek Global Kinetic Explorer (Johnson et al., 2009a).

[^35]: ^†^For the 1-step, 2-step, and 3-step models, the value for *k*~d~, the dissociation rate for RPo, was calculated using equation (17) of [@bib75]:.

[^36]: $$\frac{1}{k_{\text{d}}} = \ \frac{1}{k_{- 3}} + \ \frac{1 + \ \text{K}_{3}}{k_{- 2}} + \ \frac{\text{K}_{2} + \ \text{K}_{2}\text{K}_{3}}{k_{- 1}} + \ \frac{1}{k_{- 1}}$$.

[^37]: For the 1-step model, K~2~ = K~3~ = 0, *k*~-2~ = *k*~-3~ = ∞; for the 2-step model, K~3~ = 0, *k*~-3~ = ∞. For the 4-step model, dissociation was simulated and the result was fit to a single exponential decay to derive *k*~d~. The value for t~1/2~ was calculated as t~1/2~ = ln(2)/*k*~d~.

[^38]: c^‡^The experimental half-life (t~1/2~^exp^) was determined from promoter lifetime experiments ([Figure 2C](#fig2){ref-type="fig"}).

[^39]: \*[Appendix 1---figure 1](#fig7){ref-type="fig"}.

[^40]: \*\*The errors listed are the standard errors from the global fit as reported by Kintek Global Kinetic Explorer (Johnson et al., 2009a).

[^41]: ^†^For the 1-step, 2-step, and 3-step models, the value for *k*~d~, the dissociation rate for RPo, was calculated using equation (17) of [@bib75]:.

[^42]: $$\frac{1}{k_{\text{d}}} = \ \frac{1}{k_{- 3}} + \ \frac{1 + \ \text{K}_{3}}{k_{- 2}} + \ \frac{\text{K}_{2} + \ \text{K}_{2}\text{K}_{3}}{k_{- 1}} + \ \frac{1}{k_{- 1}}$$.

[^43]: For the 1-step model, K~2~ = K~3~ = 0, *k*~-2~ = *k*~-3~ = ∞; for the 2-step model, K~3~ = 0, *k*~-3~ = ∞. For the 4-step model, dissociation was simulated and the result was fit to a single exponential decay to derive *k*~d~. The value for t~1/2~ was calculated as t~1/2~ = ln(2)/*k*~d~.

[^44]: ^‡^The experimental half-life (t~1/2~^exp^) was determined from promoter lifetime experiments ([Figure 2C](#fig2){ref-type="fig"}).
